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dephosphorylate	 phosphatidylinositol	 3,4,5-trisphophate	 have	 received	 particular	
attention.	 In	 this	 study,	 attempts	 have	 been	 made	 to	 solve	 X-ray	 crystallographic	
structures	 of	 these	 proteins	 in	 complex	 with	 physiologically	 relevant	 inositide	 and	
phosphoinositide	ligands	or	substrate	analogs.	The	substrate	analogs	that	have	proved	









and	 ADP,	 the	 structures	 reveal	 the	 adoption	 by	 the	 protein	 of	 a	 ‘half-closed’	
conformation,	reported	previously	only	in	the	presence	of	nucleotide	alone.	
Close	scrutiny	of	the	structures	of	BiPh/protein	complexes	prompted	their	examination	
as	 potential	 inhibitors	 of	 SHIP1,	 SHIP2	 and	 AtIPK1.	 A	 fluorescence	 polarisation	 ligand	





response	with	 these	proteins.	 Similar	 screens,	which	 included	SHIP1,	were	performed	
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Figure	3.1		 Overall	 structure	 of	 AtIPK1	 (taken	 from	 Gonzalez	 et	 al,	 2010).	 Cartoon	
representation	 indicting	 the	different	 lobes	and	 the	hinge	 that	connects	 them.	
The	 N-lobe	 is	 orange,	 and	 the	 C-lobe	 green	with	 the	 CIP	 region	 coloured	 dark	
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showing	 binding	 positions	 and	 simulated	 annealing	 omit	maps.	 (A)	 AtIPK1-His	
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Figure	5.1		 Results	 of	 the	 Diversity	 Set	 II	 screen	 for	 AtIPK1,	 polarisation	 results	 for	 each	
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compounds	that	were	positive	hits	as	potential	 inhibitors	 for	AtIPK1	only	 from	
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aspects	 of	 cell	 biology.	 In	 recent	 years,	 these	molecules	 have	 been	 implicated	 in	 the	








eight	 stereoisomers	 found	 in	 nature	 in	 which	 the	 axial/equatorial	 orientation	 of	 the	
hydroxyl	groups	vary,	but	 they	will	not	be	discussed	 further	 in	 this	 text	 (Turner	et	al.,	
2012).	Myo-inositol	(Ins)	has	an	axial	hydroxyl	group	at	the	2-position	of	the	ring	with	the	
remainder	 of	 the	 hydroxyl	 groups	 positioned	 equatorially.	 It	 assumes	 a	
thermodynamically	 stable	 chair	 conformation.	 To	 help	 with	 its	 visualisation	 and	








The	 carbon	 positions	 are	 analogous	 to	 the	 turtle’s	 extremities	 and	 are	 labeled	




























1D-myo-inositol	 3-phosphate	 (Ins3P),	 catalysed	 by	myo-inositol-3-phosphate	 synthase	
(MIPS)	(Eisenberg,	1967,	Barnett	et	al.,	1973,	Sherman	et	al.,	1969a).	This	is	followed	by	
dephosphorylation	by	myo-inositol	monophosphatase	(IMP)	(Eisenberg,	1967,	Gee	et	al.,	
1988,	 Yoshikawa	 et	 al.,	 1997)	 (Figure	 1.2).	Although	 IMP	 is	 acting	 upon	 Ins3P	 in	 this	

















slime	 moulds,	 and	 perhaps	 also	 animal	 cells,	 have	 an	 added	 ability	 to	 sequentially	
phosphorylate	from	Ins3P	through	to	 IP6,	omitting	the	 lipid	 intermediate	(Brearley	and	
Hanke,	1996,	Odom	et	al.,	2000,	Ongusaha	et	al.,	1998,	Saiardi	et	al.,	1999,	Stephens	and	
Irvine,	1990,	York	et	al.,	1999).	Polyphosphoinositides	have	not	been	shown	to	exist	in	





this	 it	 is	known	that	 in	plants	and	slime	moulds	 Ins3P	can	be	synthesised	 from	 Ins	by	
phosphorylation	 via	 an	 inositol	 3-kinase	 (English	 et	 al.,	 1966,	 Loewus	 et	 al.,	 1982,	
Stephens	and	Irvine,	1990).	Furthermore,	in	animals	Ins3P	can	be	produced	as	a	product	
of	dephosphorylation	of	Ins(3,4)P2	by	inositol-3,4-bisphosphate	4-phosphatase	(Howell	











Following	 receptor	 activation	 (eg.	 receptor	 tyrosine	 kinase)	 by	 an	 agonist,	 PI3K	


















which	 goes	on	 to	 promote	 glucose	uptake.	Others	 include	proteins	 that	 promote	 cell	
growth	and	cell	survival	(Ooms	et	al.,	2009,	Manning	and	Cantley,	2007).	More	widely	
known,	PtdIns(3,4,5)P3	also	promotes	the	recruitment	of	phospholipase	C	(PLC)	resulting	
in	 IP3	 mediated	 Ca2+	 signalling.	 PtdIns(3,4,5)P3	 levels	 are	 not	 only	 governed	 by	 its	
synthesis	by	PI3K,	but	 its	degradation	by	phosphatases.	For	example,	SHIP1	and	SHIP2	
(chapter	 2)	 and	 other	 5-phosphatases,	 as	 well	 as	 the	 3-phosphatase,	 PTEN.	 It	 is	
unsurprising	given	the	diversity	of	second	messengers	and	effector	proteins	associated	
with	 phosphoinositides	 that	 their	 regulation	 has	 implications	 in	 disease.	 The	 relative	
levels	 of	 the	 different	 signalling	 phosphoinositides	 are	 dependent	 on	 the	 receptor	










maintenance	 of	 basal	 resistance	 to	 plant	 pathogens,	 apoptosis,	 and	 regulation	 of	
chromatin	structure	(Ives	et	al.,	2000),	inositol	hexakisphosphate	is	the	most	abundant	
inositol	phosphate	derivative	in	plants	and	provides	the	main	form	of	phosphorus	storage	
in	 seeds	 as	 the	 salt,	 phytate.	 It	 allows	 for	 the	 retrieval	 of	 phosphorus,	 inositol	 and	
minerals	during	development	and	germination.	It	also	accumulates	in	other	plant	tissues	
and	organs	 such	as	pollen,	 roots,	 and	 tubers	 (Raboy,	2003).	Human	grain	based	diets	
provide	excess	of	 IP6	which	can	bring	about	detrimental	effects	on	health.	This	 is	such	


















study	 of	 disease	 and	 cell	 regulatory	 processes	 has	 led	 to	 the	 synthesis	 of	 inositol	
polyphosphate	 surrogates	 as	 simple	 alternatives	 to	 chemically	 synthesising	 complex	
inositol	 polyphosphates,	 which	 is	 a	 time	 consuming	 process	 involving	 long	 multistep	
routes	and	protecting	group	chemistry	(Ward	et	al.,	1995,	Mills	et	al.,	2006,	Mills	et	al.,	
2007,	 Mills	 et	 al.,	 2008).	 Benzene	 polyphosphates	 represent	 achiral	 polyanionic	
analogues	 of	 inositol	 phosphates	 in	 which	 the	 inositol	 ring	 is	 replaced	 by	 a	 planar	
aromatic	core.	This	ceases	any	conformational	flexibility	arising	from	within	the	ring,	with	
the	 only	 flexibility	 occurring	 from	 the	 phosphate	 groups,	 which	 provides	 new	 and	
intriguing	ligands	for	inositol	phosphate	metabolising	enzymes.	Additionally,	the	nature	
of	the	benzene	ring	may	encourage	the	formation	of	new	intermolecular	ligand-protein	
interactions	 such	 as	 π–cation	 interactions	 that	 are	 not	 observed	 in	 inositol	
















































has	 been	 solved	 to	 2.9	 Å	 in	 complex	with	 Bz(1,2,4,5)P4	 (Bz3),	which	 has	 offered	 new	
insights	in	to	the	mechanism	of	INPP5B-catalysed	phosphate	group	cleavage	(Mills	et	al,	
















(Bz5),	 and	 the	 studies	 that	 followed	 between	 the	 benzene	 phosphates	 and	 type	 I	





inhibit	 Ins(1,4,5)P3	 induced	Ca2+	release	 in	permeabilised	cells	 (Vandeput	et	al.,	2007).	
Just	 like	 the	 benzene	 phosphates	 they	 have	 been	 shown	 to	 substitute	 for	 inositol	















crystal	 structure	 in	 complex	 with	 Bz1	 (Mills	 et	 al,	 2007).	 Where	 the	 aryl	 2,4,6-
trisphosphate	 motif	 docks	 to	 the	 same	 amino	 acid	 residues	 as	 Bz1,	 and	 the	 3’,5’-
bisphosphate	motif	 is	potentially	 implicated	 in	a	 cation-π	 interaction	with	an	arginine	
residue	(Mills	et	al,	2008).	These	structures,	along	with	PKBα	PH	domain	in	complex	with	
Ins(1,3,4,5)P4,	 led	 to	 the	 development	 of	 a	 docking	 protocol	 to	 identify	 drug-like	
inhibitors	by	virtual	screening	(Du-Cuny	et	al,	2009).	














the	 6-phosphate	 of	 BiPh1	 by	 a	 region	 assigned	 as	 the	 4-phosphate	 interacting	motif	




















































type	 I	 inositol	5-phosphatase	 (INPP5A),	named	as	 such	because	 it	was	 the	 first	 family	
member	 to	 be	 purified	 and	 cloned,	 which	 specifically	 only	 acts	 on	 soluble	 inositol	
phosphates	and	regulates	 intracellular	calcium	signalling.	The	rest	are	either	only	able	
to	hydrolyse	the	former	or	both	(Ooms	et	al.,	2009).	The	family	also	contains	four	yeast	
enzymes.	 Many	 of	 the	 5-phosphatases	 are	 able	 to	 remove	 the	 5-phosphate	 from	
PtdIns(3,4,5)P3	to	 yield	 PtdIns(3,4)P2,	 which	 in	 turn	 gets	 degraded	 by	 4-phosphatases	
and	terminates	PI3K/Akt	signalling.	The	pathway	 is	also	deactivated	by	3-phosphatase	
PTEN	to	yield	PtdIns(4,5)P2.	Some	5-phosphatases	are	also	active	against	PtdIns(4,5)P2,	
and/or	PtdIns(3,5)P2.	For	 these	reasons	they	are	 implicated	 in	many	disorders	such	as	
cancer,	 diabetes,	 obesity	 and	 neurodegenerative	 diseases	 (Majerus	 and	 York,	 2009).	
Additionally,	the	presence	of	phosphoinositides	and	inositol	phosphates	in	the	nucleus	
are	 implicated	 in	 the	 regulation	 of	 many	 cellular	 processes,	 including	 chromatin	
remodeling,	gene	expression,	mRNA	export	and	DNA	repair	 (Irvine,	2003,	York,	2006).	
Each	contains	a	conserved	300	amino	acid	catalytic	domain	which	is	flanked	by	various	
functional	 domains,	which	 via	 subcellular	 localisation	 and	protein-protein	 interactions	







The	 catalytic	 activity	 and	 their	 substrate	 specificities	 for	 a	 range	of	phosphoinositides	
and	 inositol	 phosphates	has	 recently	 been	 summerised	by	 Eramo	and	Mitchell,	 2016.	
The	 SH2	 (Src	 homology	 2)-containing	 inositol	 5-phosphatase	 (SHIP1)	 and	 SHIP2,	
amongst	 others,	 preferentially	 degrade	 PtdIns(3,4,5)P3	 (in	 vivo).	 Whereas	 others	










divergent	proline	 rich	domains	C-terminal	 to	 the	 catalytic	domain	 (Ooms	et	 al.,	 2009,	
Mondal	 et	 al.,	 2012).	 SHIP1	 was	 first	 identified	 as	 a	 5-phosphatase	 that	
dephosphorylates	 PtdIns(3,4,5)P3	 to	 PtdIns(3,4)P2,	 and	 Ins(1,3,4,5)P4	 to	 Ins(1,3,4)P3	
(Damen	 et	 al.,	 1996,	 Lioubin	 et	 al.,	 1996).	 The	 145	 kDa	 protein	 is	 expressed	 in	
haematopoietic	 cells	 and	 is	 an	 established	 key	 regulator	 of	 the	 immune	 system,	with	









main	 differences	 lie	 in	 the	 fact	 that	 SHIP2	 contains	 a	 SAM	 (sterile	 α	 motif)	 at	 its	 C-
terminus	 and	 the	 sequence	 divergence	 in	 their	 proline	 rich	 regions	 (Backers	 et	 al.,	
2003).	SAM	domains	span	70	residues	and	form	five-helix	bundles	with	two	interaction	
interfaces.	 They	 can	 self-associate	 forming	 dimers	 and	 possibly	 more	 extended	
structures,	 with	 suggested	 additional	 abilities	 in	 RNA	 binding.	 Originally	 SHIP2	 was	
recognised	 to	 dephosphorylate	 PtdIns(3,4,5)P3	and	 Ins(1,3,4,5)P4,	 but	 recently	 in	 vitro	
studies	 suggest	 a	 wider	 and	 preferred	 substrate	 specificity	 of	 Ins(1,2,3,4,5)P5	 >	
Ins(1,3,4,5)P4	>	PtdIns(3,4,5)P3	≈	PtdIns(3,5)P2	≈	Ins(1,4,5,6)P4	(Pesesse	et	al.,	1998,	Chi	
et	al.,	2004).	It	is	more	ubiquitous	than	SHIP1	and	is	expressed	in	both	haematopoietic	
and	non-haematopoietic	 tissues,	 including	brain,	 skeletal	muscle,	 heart,	 and	 liver	 and	
kidney	 tissues,	 the	 latter	 to	 a	 lesser	 extent.	 SHIP2	 plays	 a	 negative	 role	 in	 insulin	
signalling	 as	 has	 been	 demonstrated	 in	 many	 in	 vitro	 cellular	 models,	 where	




glucose	 uptake	 and	 glycogen	 synthesis	 (Blero	 et	 al.,	 2001,	Wada	 et	 al.,	 2001).	 SHIP2	
overexpression	 in	mice	 reduces	 glucose	 tolerance	 and	 increases	 body	 weight	 due	 to	
decreased	 insulin-stimulated	 Akt	 phosphorylation	 (Kagawa	 et	 al.,	 2008).	 On	 the	




α-aminocholestane	 (3AC),	 in	 cancer	 cell	 lines	 decreases	 Akt	 phosphorylation.	
Observations	 included	 reduced	multiple	myeloma	 (MM)	cell	 growth	and	viability,	 and	
decreased	IGF-1-induced	phosphorylation	of	Akt	 in	the	presence	of	3AC	(Brooks	et	al.,	
2010).	Additionally,	pan-SHIP1/2	inhibitors	in	breast	cancer	cell	 lines	prohibited	SHIP2-




Crystal	 structures	 of	 five	 of	 the	 inositol	 5-phosphatases	 are	 currently	 available.	 Four	
structures	are	available	of	type	II	inositol	5-phosphatase	(INPP5B)	alone,	all	in	complex	
with	 ligands;	 diC8PtdIns(4)P1	 (PDB	 3MTC),	 diC8PtdIns(3,4)P2	 (PDB	 4CML),	 and	 most	
recently	 with	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	 and	 benzene	 1,2,4,5-
tetrakisphosphate	(BiPh3/Bz3-	see	section	1.1.3)	(PDB	5A7I	&	5A7J)	(Trésaugues	et	al.,	
2014,	 Mills	 et	 al.,	 2016a).	 The	 5-phosphatase	 domain	 of	 yeast	 Schizosaccharomyces	
pombe	 SPsynaptojanin	 in	 complex	 with	 Ins(1,4)P2	 and	 SHIP2	 bound	 with	 biphenyl	
2,3’,4,5’,6-pentakisphosphate	 are	 also	 available	 (PDB,	 1I9Z	 &	 4A9C,	 respectively)	













The	 two	 published	 crystal	 structures	 of	 SHIP2cd	 are	 in	 the	 same	 conformation	 and	
crystallise	under	similar	conditions	in	the	same	space	group,	regardless	of	the	presence	
of	a	 ligand	or	not.	The	protein	crystallises	with	two	molecules	 in	the	asymmetric	unit,	
with	 one	molecule	 contacting	 a	 symmetry	 related	molecule	 via	 a	 flexible	 loop	 that	 is	
consequently	 stabilised,	 it	 is	 disordered	 in	 the	 other	 molecule	 as	 it	 lacks	 the	 same	
contacts	with	 a	 symmetry	mate.	A	molecule	of	BiPh1	was	only	 found	 in	 the	 inositide	
binding	 site	 of	 the	 molecule	 with	 the	 stabilised	 loop.	 The	 inositide	 binding	 site	 was	
originally	 identified	 from	 the	 complex	 between	 the	 related	 INNP5B	 and	 PtdIns(4)P.	












































































Much	 is	 still	 left	 undiscovered	when	 considering	 the	mechanism	of	 SHIP1	 and	 SHIP2,	
and	indeed	the	rest	of	the	5-phosphatases,	although	the	first	evidence	and	speculations	









there	 is	 an	 added	 lack	 of	 in	 vitro	 studies,	 as	most	 characterisation	 has	 been	 done	 in	
terms	of	 its	 regulation	and	 its	 regulatory	 influence	of	 the	pathways	 it	 is	 implicated	 in	
within	live	cells.	Therefore	a	key	objective	in	this	work	was	to	clone	Ship1	(INPPL1)	and	
its	catalytic	domain	 in	 to	a	suitably	selected	expression	vector	 for	overexpression	and	
subsequent	 protein	 purification	 for	 use	 in	 in	 vitro	 binding	 and	 enzymatic	 assays.	
Secondly,	attempts	to	crystallise	the	catalytic	domain	of	SHIP1	(SHIP1cd)	were	made	as	




















2.2).	 Synthesis	 was	 carried	 out	 by	 MWG	 Eurofins	 and	 the	 lyophilized	 primers	 were	
stored	 as	 100	 μM	 stocks	 in	 nuclease	 free	 water	 (Qiagen)	 at	 -20	 °C.	 Diluted	 working	




All	 PCR	was	 carried	 out	 in	 a	MJ	 Research	 Dyad	 Thermal	 Cycler.	 PCR	 amplification	 of	
INPP5Dcd	 and	 INPP5D	 was	 performed	 using	 Phusion	 High	 Fidelity	 Polymerase	 (New	
England	 Biolabs)	 as	 per	manufacturer’s	 instructions	 and	 using	 the	 primer	 sequences,	
annealing	 temperatures,	 and	elongation	 times	provided	 in	 Table	2.	 .	Deoxynucleotide	



























Plasmid	 purification	 from	 E.	 coli	 cells	 was	 performed	 using	 the	 Wizard®	Plus	SV	
Miniprep	 DNA	 Purification	 System	 (Promega)	 following	 suppliers	 standard	 protocol.	





Rosetta	 expression	 host	 E.	 coli	 cells	 (Novagen)	 were	 streaked	 on	 to	 a	 LB	 agar	 plate	
containing	 34	 μg/mL	 chloramphenicol	 (to	 maintain	 the	 chloramphenicol-resistant	
pRARE	plasmid)	from	a	-80	°C	stored	glycerol	stock	and	 incubated	O/N	at	37	°C.	From	
the	 resulting	 growth,	 a	 single	 colony	 was	 selected	 to	 inoculate	 5	 mL	 of	 LB	 medium	
supplemented	with	 chloramphenicol,	 and	 grown	 in	 a	 37	 °C	 shaking	 incubator	O/N	 at	
220	rpm.	The	resulting	culture	was	used	to	inoculate	SOB	medium	in	a	ratio	of	3:500	mL	
(v/v)	and	incubated	at	30	°C	with	shaking	at	220	rpm	until	an	OD595	of	~0.5	was	reached.	
All	 further	 steps	were	 carried	out	 on	 ice	or	 4	 °C,	 and	with	 ice-cold	buffers.	 A	 10	min	
centrifugation	at	 5000	 rpm	of	 the	 ice-cold	 culture	was	used	 to	obtain	 a	pellet,	which	
after	 decanting	 off	 the	 supernatant,	 was	 gently	 re-suspended	 in	 100	 mL	 TB	 buffer	

















and	 the	 appropriate	 selective	 antibiotics.	 The	 plate	was	 then	 inverted	 and	 incubated	
O/N	at	 37	 °C.	 The	next	day,	 a	 single	 colony	was	picked	 from	 the	plate	using	 a	 sterile	






















Under	 sterile	 conditions,	 cultures	 were	 spread	 on	 to	 three	 plates	 containing	 LB	 agar	
media	plus	the	appropriate	selective	antibiotics	and	incubated	O/N	at	37	°C.	Liquid	LB	(1	
mL)	was	added	to	each	plate	and	scraped	using	a	glass	spreader	to	release	the	bacteria	
from	 the	plate.	The	 resuspended	bacteria	was	aliquoted	 in	 to	1.5	mL	microcentrifuge	












in	casting	 frames	on	a	casting	stand	(Bio-Rad),	until	 the	gel	 level	was	approximately	2	
cm	from	the	top	of	the	front	plate.	Drops	of	 isopropanol	were	immediately	applied	to	
the	top	of	the	gel	until	it	was	even	and	free	of	bubbles,	before	being	left	to	polymerise	













loading	 buffer	 (see	 appendix	 2)	 was	 used	 to	 re-suspend	 the	 resulting	 pellet	 before	
boiling	 for	 7	min.	Once	 cooled	 slightly	 the	 sample	was	 pulse	 centrifuged.	 	 If	working	
with	purified	or	 partially	 purified	protein,	 centrifugation	was	 skipped	 and	1:3	 (v/v)	 of	
sample	to	3	x	SDS	loading	buffer	was	used.	
	
The	 comb	was	 removed	 from	a	pre-prepared	polyacrylamide	gel	 and	 the	wells	 gently	
rinsed	with	dH2O	before	being	placed	 in	 the	electrophoresis	 tank	 (Bio-Rad)	 filled	with	
SDS	running	buffer	(see	appendix	2)	to	cover	the	gel.	Typically	10	μL	of	the	sample	was	
loaded	 in	 to	 a	 well,	 with	 a	 protein	 molecular	 weight	 marker	 loaded	 as	 per	
manufacturer’s	instructions	in	an	adjacent	well.	The	gel	ran	at	150	–	180	V	until	the	dye	
front	 was	 approximately	 1	 cm	 from	 the	 bottom	 of	 the	 gel.	 Once	 extracted	 from	
between	 the	 glass	 plates	 and	 rinsed	 with	 dH2O,	 the	 gel	 was	 stained	 using	 either	
















The	 bacterial	 suspensions	 of	 the	 expression	 culture	 pellets	 were	 recovered	 from	 the	
freezer	 and	 thoroughly	 thawed	 on	 ice.	 Mechanical	 cell	 disruption	 was	 achieved	 by	
French	 press	 at	 a	 working	 pressure	 of	 17000	 PSI,	 with	 a	 maximum	 of	 30	 mL	 of	
suspension	being	loaded	in	to	the	cell	at	any	one	time.	The	suspension	and	lysate	were	
kept	on	ice	during	all	steps	and	each	suspension	was	subjected	to	3	passes	through	the	
French	 pressure	 cell	 to	 ensure	 complete	 homogenisation.	 Ultracentrifugation	 of	 the	
lysate	 at	 40000	 rpm	 and	 4	 °C	 for	 1	 h	 was	 used	 to	 remove	 the	 cell	 debris,	 and	 the	






buffer	A.	A	gradient	of	 imidazole	was	applied	 to	 the	column	over	50	mL	 from	20	mM	
(buffer	 A)	 to	 500	 mM	 (buffer	 B)	 (see	 Appendix	 2),	 followed	 by	 washing	 with	 50	 mL	
buffer	B.	Fractions	were	collected	throughout;	10	mL	during	the	wash	phases	and	2	mL	
during	the	imidazole	gradient.	The	absorbance	of	the	eluate	was	monitored	at	280	nm,	
and	 from	 the	 resulting	 UV	 absorbance	 trace	 fractions	 containing	 protein	 could	 be	
identified.	A	 sample	was	 taken	of	 each	UV	absorbing	 fraction	 to	be	 analysed	by	 SDS-
PAGE.	Fractions	confirmed	to	contain	protein	were	pooled	and	concentrated	using	an	
Amicon®	 stirred	 ultrafiltration	 cell	 with	 a	 10	 kDa	 cut	 off	 membrane	 to	 a	 volume	 of	
approximately	 2.2	 mL	 in	 preparation	 for	 loading	 on	 to	 a	 HiLoad	 16/60	 Superdex	 75	
column	(GE	Lifesciences)	for	size	exclusion	chromatography.	
	
Again,	 the	 column	 was	 use	 in	 tandem	 with	 an	 ÄKTA	 prime	 purification	 system	 and	
equilibrated	with	240	mL	(two	volumes)	of	sepharose	buffer	(see	Appendix	2).	After	the	







before	 being	 pooled	 and	 concentrated.	 Protein	 concentration	 was	 estimated	 using	 a	







SHIP2cd-His,	 following	 the	manufacturers	 guidelines.	 In	 general,	 the	 protein	was	 first	
concentrated	to	typically	1	–	2.5	mL	to	reduce	the	reaction	volume,	and	the	suggested	




Although	 the	 conditions	 for	 the	 crystallisation	 of	 SHIP2cd	 were	 already	 established	
(Mills	 et	 al.,	 2012,	 Trésaugues	 et	 al.,	 2014),	 and	 therefore	 high	 throughput	 screening	




plus	 10	 mM	MgSO4,	 was	 incubated	 at	 16	 °C	 prior	 to	 setting	 drops	 in	 a	 1:2	 ratio	 of	
protein	to	precipitant.	Crystals	formed	as	needle	clusters	within	48	hr	and	were	allowed	















X-ray	 diffraction	 data	 was	 indexed	 and	 auto	 processed	 using	 Xia2.	 Molecular	
replacement	 was	 performed	 using	 Phaser-MR	within	 the	 Phenix	 suite	 (McCoy,	 2007)	
and	 structures	 refined	 using	 Phenix	 refine	 (Afonine	 et	 al.,	 2005).	 Coot	 (Emsley	 et	 al.,	











An	expression	clone	of	 INPPL1cd	 (SHIP2cd)	 in	the	vector	pNIC-MBP	was	purchased	via	
the	 Structural	 Genomics	 Consortium	 (SGC)	 from	 Source	 BioScience	 (Clone	 accession	
TC124029).	 The	 clone	 was	 supplied	 as	 an	 E.	 coli	 stock	 on	 an	 agar	 slope	 which	 was	
treated	as	per	the	supplier’s	recommendations	before	purifying	the	plasmid	using	the		
Wizard®	Plus	SV	Miniprep	DNA	Purification	System	(Promega).	To	prepare	the	vector	it	
was	 transformed	 into	 stellar	 competent	 E.	 coli	 cells	 (Clontech)	 and	 single	 kanamycin	
resistant	 colonies	 selected,	 from	which	 overnight	 cultures	 were	 grown	 for	 high	 yield	
plasmid	extraction.	The	plasmid	was	transformed	into	expression	host,	E.	coli	Rosetta2	
cells,	 single	 kanamycin	 resistant	 colonies	 selected,	 and	 the	 expression	 of	 SHIP2cd-His	
tested	 via	 small	 scale	 expression	 tests	 (see	 section	 2.2.13).	 Parameters	 investigated	
were;	 temperature,	 IPTG	 concentration	 and	 length	 of	 incubation	 post	 IPTG	 addition	
(results	not	shown).	
	
Subsequently,	 large	 scale	expression	 cultures	were	 set	up	 for	purification	of	 SHIP2cd-
His.	 Two	1	 L	 cultures	were	 set	 up	 and	 expression	 carried	 out	 as	 outlined	 in	methods	
(section	2.2.16)	using	0.2	mM	IPTG	to	induce	protein	expression	(results	not	shown).	It	
was	 later	 found	 that	 4	 L	 of	 culture	 was	 necessary	 to	 produce	 enough	 protein	 for	
crystallography	studies.	
	
SHIP2cd-His	 protein	was	 purified	 as	 per	 the	method	 described	 in	 section	 2.2.17.	 The	
lysate	 of	 the	 2	 L	 culture	 was	 centrifuged	 to	 remove	 cell	 debris	 before	 loading	 the	








16-20	 (lanes	6-8).	As	 these	contaminated	 fractions	also	contained	 the	highest	yield	of	
SHIP2cd	 they	 were	 pooled,	 along	 with	 fractions	 22-24,	 for	 concentrating	 before	 size	
exclusion	chromatography	on	a	HiLoad	16/600	Superdex	75	pg	column	(GE	Healthcare	
Life	 Sciences),	 performed	 according	 to	 section	 2.2.17.	 Lane	 3	 shows	 the	 lysate	 after	
loading	on	to	the	NiNTA	column	and	reveals	that	some	of	the	SHIP2cd-His	protein	did	











stained	with	 InVision™	 His-tag	 In-gel	 Stain	 (Novex	 by	 Life	 Technologies),	 used	 as	 per	









TEV	 plus	 protease	 (Promega)	 after	 concentrating	 the	 protein	 to	 2.5	mL	 volume.	 The	









which	 were	 analysed	 by	 SDS-PAGE	 using	 a	 12.5%	 acrylamide	 gel,	 with	 the	 aim	 to	














The	 products	 of	 the	 His-tag	 cleavage	 reaction	 were	 loaded	 on	 to	 a	 5	 mL	 NiNTA	
superflow	cartridge	(Qiagen),	equilibrated	with	buffer	A	(see	appendix	2),	at	a	flow	rate	
of	0.5	mL/min	in	a	continuous	loop	for	30	min.	Elution	of	the	column	with	buffer	A	at	
1ml/min	 yielded	 SHIP2cd,	 collected	 in	 a	 10	 mL	 fraction	 and	 five	 subsequent	 2	 mL	




a	 final	 round	 of	 size	 exclusion	 chromatography	 (results	 not	 shown).	 Final	 purified	
SHIP2cd	was	concentrated	to	9	mg/mL	and	snap	frozen	before	storage	at	-80	°C.	Figure	
2.7	 shows	 a	 sample	 of	 this	 preparation.	 The	 gel	 is	 overloaded	 to	 visualise	 the	
occurrence	of	contaminants,	which	are	negligible	when	compared	to	the	concentration	
of	 SHIP2cd.	 Final	 protein	 yield	 approximated	 to	 9	 mg/mL	 obtained	 from	 4	 L	 of	
expression	culture.	 	







SHIP2cd	 was	 crystallised	 as	 per	 section	 2.2.19,	 which	 was	 adapted	 from	 a	 previous	
method	 published	 by	 Mills	 et	 al,	 2012.	 Crystals	 grew	 as	 individual	 plates	 or	 rods,	
appearing	 after	 2	 days	 and	 continued	 to	 grow	 for	 3-5	 days.	 Crystallisation	 was	
attempted	 several	 times	 and	was	 not	 consistent,	 resulting	 in	 a	 lower	 than	 hoped	 for	
yields	of	 crystals.	Nevertheless,	 individual	 crystals	were	harvested	 into	cryoprotectant	















Both	 co-crystallisation	and	 soaking	methods	were	 implemented	 in	attempts	 to	obtain	
crystals	 of	 	 protein/ligand	 complexes.	 As	 well	 as	 optimisatisation	 of	 the	 previously	
published	 conditions,	 exploration	 of	 alternative	 conditions	 via	 high-throughput	
screening	was	also	attempted.	Prior	to	the	work	of	Mills	and	coworkers	(2012),	the	only	
structure	 of	 a	 5-phosphatase	 catalytic	 domain	 that	 had	 been	 reported	 is	 that	 of	
Schizosaccharomyces	 pombe	 synaptojanin	 (SPsynaptojanin).	 The	 structure	 was	
determined	 in	 complex	 with	 a	 soluble	 inositol	 1,4-bisphosphate	 product	 of	 5-
phosphatase	 action	 on	 inositol	 1,4,5-trisphosphate	 (Tsujishita	 et	 al.,	 2001).	 As	 such,	
neither	structure	inform	how	5-phosphatases	as	a	class	co-ordinate	the	lipid	moieties	of	
their	phosphoinositide,	particularly	PtdIns(3,4,5)P3,	substrates.	Since	then,	the	work	of	
Trésaugues	 et	 al.,	 2014,	 provided	 a	 number	 of	 structures	 of	 the	 catalytic	 domains	 of	
other	 5-phosphatase	 family	 members:	 INPP5B	 in	 apo,	 PtdIns4P-bound	 and	















Space	Group P	21	Unit	Cella,	b,	c		(Å)α,	β,	γ	(°) 44.7,	61.1,	114.292.19Resolution	(Å) 57.08-2.75	(2.88-2.75)Rmerge		(%) 10.7	(39.2)<I/σ(I)> 7.4	(2.1)CC	1/2 0.949	(0.630)Completeness	(%) 97.8	(97.8)Multiplicity 2.8	(2.7)Wilson	B-factor 6.326






During	 the	 course	 of	 this	 study	 a	 second	 structure	 of	 SHIP2cd	 was	 solved	 to	 2.8	 Å,	
Protein	Data	 Bank	Acession	 3NR8	 (Trésaugues	 et	 al.,	 2014),	 again	 in	 P21	 space	 group	
and	the	same	unit	cell	as	the	apo	structure	presented	here.		
	
Just	 like	 the	 previously	 published	 structures,	 SHIP2cd	 crystallised	with	 two	molecules	
(chains	A	and	B)	in	the	asymmetric	unit	(AU).	These	align	to	each	other	with	a	RMSD	of	
0.319	(Figure	2.9	–	A).	Crystallisation	in	this	space	group	and	unit	cell	may	be	expected	
as	 the	 same	 recombinant	protein	 and	 very	 similar	 crystallisation	methods	were	used.	
Here,	 both	molecules	 interact	with	 symmetry	 related	molecules	 in	 neighbouring	AUs,	

















B	 interacts	with	a	chain	A	 lattice	neighbour,	with	 the	converse	being	 true	 for	 chain	A	
(Figure	2.2).	 In	 chain	B,	 interactions	occur	 at	 the	apex	of	 the	extended	 loop	between	
P678,	H-bonded	with	M502	and	with	hydrophobic	 interaction	with	V525,	both	of	 the	
symmetry	 related	 molecule.	 These	 interactions,	 and	 that	 of	 R479	 of	 the	 neighbour	








Figure	 2.10	 –	 Interactions	 between	 the	 (P4IM)-containing	 loop	 of	 chain	 B,	 and	 a	 symmetry	 related	 lattice	







The	 P4IM-containing	 loop	 of	 chain	 A	 is	 directed	 towards	 a	 disordered	 region	 in	 the	





















Figure	2.12	–Alignments	 of	 apo	 SHIP2cd	 (magenta)	 and	SHIP2cd	BiPh(2,3’,4,5’,6)P5	 structures	 (cyan)	 (Mills	 et	 al.,	
2012).	 BiPh(2,3’,4,5’,6)P5	 is	 represented	 as	 sticks	 and	 coloured	 by	 element.	 (A)	 Cartoon	 representation	 of	 the	



















the	 interactions	with	 the	symmetry	 related	molecule	 in	 the	 lattice	 (chain	B	only).	The	
structural	 organisation	 of	 this	 region	 is	 also	 only	 defined	 in	 chain	 B	 of	 a	 previously	












in	 the	 active	 site	 of	 SHIP2	 remains	 a	 concern,	 even	 despite	 the	 molecular	 dynamics	





presented	 in	 this	 thesis,	 the	 structure	 reported	 here	 does	 not	 offer	 insight	 to	 the	
unanswered	 question	 of	 the	 co-ordination	 of	 the	 scissile	 5-phosphate	 of	 inositide	 or	
phosphoinositide	 substrates.	 To	 obtain	 further	 information,	 an	 attempt	was	made	 to	












selection	 of	 plasmids	 available	 for	 purchase,	 pNIC-MBP,	which	 INPPL1cd	 is	 in,	 is	 not.	
Therefore,	 it	 was	 necessary	 to	 seek	 out	 appropriate	 alternatives	 that	 would	 provide	
equally	 successful	 yields	 of	 active	 protein.	 As	 SHIP2	 and	 SHIP1	 are	 close	 homologues	
and	their	5-phosphatase	domains	share	63.9	%	identity,	sensible	options	would	include	
vectors	similar	to	pNIC-MBP.	This	plasmid	adds	a	MBP-TVMV-His6-TEV	fusion	to	the	N-







2006,	 Eschenfeldt	 et	 al.,	 2009)	 (DNASU-plasmid	 repository).	 The	 pNIC28-Bsa4	
expression	vector	was	also	selected	due	to	its	extensive	use	by	SGC	to	successfully	clone	
and	 express	 many	 mammalian	 proteins;	 adding	 a	 His-TEV	 N-terminal	 fusion	 to	 the	
cloned	expression	target	(Gileadi	et	al.,	2008,	Savitsky	et	al.,	2010)	(GenBank	EF198106).	
















high	 percentage	 identity	 in	 their	 catalytic	 domains,	 the	 sequence	 for	 the	 catalytic	





primer	 sequences,	 annealing	 temperature	 and	 elongation	 time	provided	 in	 Table	 2.2.	




To	 remove	 primers	 and	 other	 contaminants,	 the	 PCR	 products	 were	 purified	 by	 gel	
extraction	using	the	Wizard®	SV	Gel	and	PCR	Clean-Up	System	(Promega)	after	agarose	
gel	electrophoresis	(see	section	2.2).	The	PCR	products	shown	in	Figure	2.13	were	the	
expected	 fragment	 sizes	 for	 full	 length	 SHIP1	 and	 SHIP1cd;	 3567	 bp	 and	 957	 bp,	
respectively.	
	 	
Gene	name	 Template	IMAGE	ID Forward	primer	(5'	to	3') Reverse	primer	(5'	to	3') Fragment	size	(bp) Annealing	temperature	(°C) Elongation	time	(sec)
INPP5D 8322634 TACTTCCAATCCATGGTCCCCTGCTGGAACCAT TATCCACCTTTACTGTCACTGCATGGCAGTCCTGCC 3567 57 70




The	 purified	 PCR	 product	 was	 treated	 with	 T4	 DNA	 polymerase	 (Clontech)	 in	 the	




The	 pNIC-Bsa4	 vector	 was	 purchased	 from	 the	 SGC	 (Source	 BioScience)	 and	 was	
supplied	 as	 an	E.	 coli	 stock	 on	 an	 agar	 slope	which	was	 treated	 as	 per	 the	 supplier’s	
recommendations	 before	 purifying	 the	 plasmid	 using	 the	 Wizard®	 Plus	 SV	 Miniprep	
DNA	Purification	System	(Promega).	To	prepare	vector,	 it	was	transformed	into	Stellar	
competent	 E.	 coli	 cells	 (Clontech),	 single	 kanamycin	 resistant	 colonies	 selected,	 from	
which	O/N	cultures	were	grown	for	later	plasmid	extraction.	The	plasmid	was	digested	
with	 BsaI-HF	 restriction	 enzyme	 (New	 England	 Biolabs)	 as	 per	 the	 manufacturer’s	
















To	 generate	 the	 cohesive	 ends	 required	 for	 ligation	 independent	 cloning,	 the	 BsaI	
digested	plasmid	was	treated	with	T4	DNA	polymerase	in	the	presence	of	dGTP	for	30	
min	 at	 11	 °C	 followed	 by	 20	 min	 at	 75	 °C;	 creating	 single	 stranded	 5’	 overhangs	
complementary	to	the	PCR	products.	
	
Annealing	of	 the	 treated	plasmid	and	 insert	was	achieved	by	 incubating	a	 ratio	of	2:1	
(v/v)	plasmid	 to	 insert	at	 room	temperature	 followed	by	 incubation	on	 ice	 for	10	min	
before	transforming	in	to	stellar	competent	E.	coli	cells.	Only	a	few	transformants	were	
generated	 for	 SHIP1cd	 and	 none	 for	 full	 length	 SHIP1.	 Therefore,	 only	 SHIP1cd	 was	














Two	 kanamycin	 resistant	 colonies	 were	 selected	 and	 grown	 overnight	 in	 LB.	 Colony	
screening	was	carried	out	on	the	overnight	cultures	via	PCR	amplification	using	GoTaq®	
G2	Flexi	DNA	Polymerase	(Promega)	as	per	manufacturer’s	instructions	and	detailed	in	






rev	 primers	 (Gileadi	 et	 al.,	 2008),	 which	 verified	 the	 correct	 sequence	 before	
















Two	 single	 colonies	 were	 selected	 from	 the	 transformation	 plate	 to	 cultivate	 starter	
cultures	for	subsequent	expression	testing.	Expression	tests	were	carried	as	outlined	in	





Figure	2.16	–	 Small	scale	expression	testing	of	 SHIP1cd-His	by	E.	coli	Rosetta2	 cells.	SDS–PAGE	analysis	on	a	10%	
acrylamide	 gel	 of	 whole	 cell	 pellets	 from	 IPTG	 induced	 cultures	 originating	 from	 two	 separate	 transformation	
colonies.	
	A	–	non-ITPG	induced	cultures	(1)	Protein	molecular	weight	marker.	(2)	Culture	A.	(3)	Culture	B.		












glucose	 supplementation	 to	 suppress	 expression	 during	 the	 growth	 phase.	 This	 is	 as	




carried	 forward	 to	 purify	 SHIP1cd-His.	 Two	 1	 L	 cultures	 were	 set	 up	 and	 expression	














SHIP1cd-His	 protein	was	 purified	 as	 per	 the	method	 described	 in	 section	 2.2.17.	 The	
lysate	of	the	2	L	culture	from	section	2.3.2	was	centrifuged	to	remove	cell	debris	before	













SHIP1cd-His	 from	 the	 UV	 absorbance	 trace	 during	 nickel	 affinity	 purification.	 The	
overexpressed	SHIP1cd-His	(39.5	kDa)	can	be	seen	most	prominently	in	fractions	16-24	
(lanes	3-7),	with	the	most	heavy	contamination	occurring	in	fractions	16-20	(lanes	3-5).	
As	 these	 contaminated	 fractions	 also	 contained	 the	 highest	 yield	 of	 SHIP1cd-His	 they	




Two	 peaks	 were	 observed	 on	 the	 resulting	 UV	 trace	 from	 the	 size	 exclusion	
chromatography,	albeit	not	overly	distinctive	with	some	observed	overlap.	As	the	first	
peak	 is	 expected	 to	 be	 the	 larger	 contaminant	 proteins	 eluting	 in	 the	 void	 volume,	
samples	of	the	fractions	from	the	wide	second	peak	were	analysed	by	SDS-PAGE	(Figure	
2.19).	 SHIP1cd-His	 appeared	 to	 be	 present	 in	 fractions	 7-17	 (lanes	 2-7)	 in	 varying	
magnitudes	and	co-eluted	with	contaminants.	 It	 is	 likely	there	 is	some	protein-protein	
interactions	occurring	between	SHIP1cd	and	the	contaminants,	accounting	for	the	wide	








DTT	 or	 TCEP,	 see	 section	 2.2.9	 and	 appendix	 2	 for	 more	 details.	 A	 HiLoad	 16/600	
Superdex	 200	 pg	 (GE	 Healthcare	 Life	 Sciences)	 was	 also	 utilised	 in	 an	 attempt	 to	
improve	 separation	 between	 SHIP1cd-His	 and	 the	 contaminating	 proteins	 during	 size	




for	 AtIPK1	 (Chapter	 3),	 which	 were	 pH	 7.5.	 This	 may	 have	 been	 too	 close	 to	 the	
isoelectric	point	of	SHIP1cd-His	and	could	have	rendered	some	of	the	protein	insoluble,	
resulting	in	aggregation	and	interactions	with	contaminating	proteins.	Nevertheless,	as	
will	 be	 seen	 later	 on	 in	 this	 text,	 soluble	 and	 catalytically	 active	 SHIP1cd	protein	was	
obtained.	
	 	
Figure	2.19	 -	 Size	 exclusion	 chromatography	of	 SHIP1cd-His.	 SDS-PAGE	 analysis	 on	a	 10%	acrylamide	 gel	 of	 elute	
fractions	recovered	from	a	sepharose	gel	filtration	column.	(1)	Protein	molecular	weight	marker.	(2-8)	Column	elute	






stained	with	 InVision™	 His-tag	 In-gel	 Stain	 (Novex	 by	 Life	 Technologies),	 used	 as	 per	
manufacturer’s	 guidelines.	 Subsequently,	 the	 same	 gel	was	 stained	with	 a	 Coomassie	
blue	stain	as	per	section	2.2.15	(Figure	2.20).	As	the	sample	was	highly	concentrated	a	
1:2	 dilution	 of	 the	 protein	 was	 used.	 The	 InVision	 stain	 binds	 specifically	 to	 the	
6xHistidine	tag	and	can	be	used	to	accurately	detect	the	presence	of	His-tagged	fusion	
proteins	due	to	its	fluorescent	properties.	Its	excitation	maximum	is	at	a	wavelength	of	











The	 final	 purified	 protein	 contains	 contaminants	 and	 it	 appears	 there	 are	 truncated	
versions	of	SHIP1cd-His,	as	can	be	seen	by	the	right	hand	side	of	the	gel	in	Figure	2.20	
where	 only	 proteins	 with	 a	 histidine-tag	 are	 stained.	 This	 could	 be	 due	 to	 the	
production	 of	 truncates	 during	 expression,	 degradation	 of	 SHIP1cd-His	 and/or	
hydrolysis	by	proteases.	Having	these	presumably	non-folded	and	truncated	versions	of	




avoid	 any	 interference,	 which	 could	 perhaps	 occur	 by	 additional	 non-canonical	
interactions.	 Cleavage	 of	 the	 6xHistidine	 tag	 was	 set	 up	 post	 size	 exclusion	
chromatography	using	Pro	TEV	plus	protease	(Promega)	after	concentrating	the	protein	




which	 were	 analysed	 by	 SDS-PAGE	 using	 a	 12.5%	 acrylamide	 gel,	 with	 the	 aim	 to	








The	 products	 of	 the	 His-tag	 cleavage	 reaction	 were	 loaded	 on	 to	 a	 5	 mL	 NiNTA	
superflow	cartridge	(Qiagen),	equilibrated	with	buffer	A	(see	appendix	2),	at	a	flow	rate	






















Figure	2.22	 -	 Immoblised	metal	 affinity	purification	post	proteolytic	 cleavage	of	 SHIP1cd-His	with	 TEV	protease.	










As	 can	 be	 seen	 in	 Figure	 2.23,	 removing	 the	 6xHistidine	 tag	 from	 SHIP1cd-His	 also	
removes	many	of	the	contaminants	when	compared	to	the	non-cleaved	protein.		
	 	












The	 SWISS-MODEL	automated	protein	 structure	homology-modelling	 server	 is	 able	 to	
generate	 3D	models	 for	 proteins	 where	 experimental	 data	 is	 not	 available.	 It	 allows	
users	 to;	 conveniently	 search	 for	 suitable	 templates	 using	 sensitive	 Hidden	 Markov	
Model	 searches	 against	 the	 SWISS-MODEL	 Template	 Library,	 analyse	 alternative	







SHIP1cd	sequence	used	 in	 this	study,	 this	 resulted	 in	a	suggestion	that	a	structure	 for	






The	SHIP2cd	structure	 from	this	 study	was	used	as	a	 template	 for	 the	SHIP1cd	model	











in	 complex	with	 ligands	 (Mills	 et	 al.,	 2012,	Mills	 et	 al.,	 2016b,	 Tsujishita	 et	 al.,	 2001).	
These	 proteins	 display	mutually	 conserved	 residues	within	 their	 binding	 pockets	 that	
coordinate	 the	 various	 ligands.	 Five	 of	 those	 residues	 are	 involved	 in	 coordination	 of	
BiPh1	 in	 to	 the	active	site	of	SHIP2cd;	K541,	Y661,	R682	&	N684	 (Figure	2.25).	Where	
K541	coordinates	the	P1	site;	defined	according	to	structures	of	 INPP5B	with	PtdIns4P	
and	PtdIns(3,4)P2,	and	the	5-	and	6-	hydroxyl	site.	These	positions	are	occupied	by	P3’	
and	 P5’	 of	 BiPh1,	 respectively.	 The	 remaining	 conserved	 residues	 contact	 the	 P4	
position,	 P2	 of	 BiPh1.	 When	 overlaying	 these	 residues	 from	 SHIP2cd	 with	 the	
corresponding	residues	of	the	SHIP1cd	model,	they	align	quite	accurately	but	with	one	
key	difference;	R682	becomes	K682	 in	SHIP1cd	 (Figure	2.25).	 It	 is	one	of	 the	 residues	
that	contacts	the	P4	position	that	is	thought	to	be	the	position	that	confers	specificity	
since	 the	 5-phosphatases	 selectively	 hydrolyse	 PI(4,5)P2	or	 PI(3,4,5)P3.	 Therefore	 this	














Out	 of	 the	 ten	 enzymes	 in	 the	 inositol	 polyphosphate	 5-phosphatase	 family,	 only	
SHIP1cd	and	SHIP2cd	are	described	to	have	the	extended	P4IM-containing	loop	(Mills	et	
al.,	2012).	Small	changes	in	this	active	site	loop	can	be	seen	between	the	SHIP1cd	model	
and	 the	 SHIP2cd	 structure.	 This	 is	 also	 observed	 in	 the	 pre-existing	 structures	 of	
SHIP2cd	 in	 the	PDB.	The	homology	modelling	of	SHIP1cd	places	 this	 loop	 in	 the	same	
length	 of	 polypeptide	 as	 in	 the	 SHIP2cd	 structure,	 as	 can	 be	 seen	 by	 observing	 the	
secondary	 structure	 (Figure	 2.26).	 The	 two	 antiparallel	 β-sheet,	 β10	 &	 β11,	 are	
connected	 by	 a	 β-turn	 and	 are	 composed	 of	 the	 same	 number	 of	 residues	 in	 both	
structures.	However,	there	is	only	50%	identity	in	these	secondary	structure	elements,	
again	 supporting	 the	hypothesis	 that	 the	P4IM-containing	 loop	 is	not	 critical	 in	 ligand	
binding	and	can	likely	adjust	to	a	variety	of	ligands	interacting	with	the	binding	pocket.	
Conversely,	 the	 electron	 density	 map	 for	 this	 region	 in	 SHIP2cd	 would	 ideally	 be	 of	
higher	resolution	and	more	whole	(section	2.3.6),	which	may	have	led	to	a	partial	model	



































































































It	 is	 noteworthy	 to	 mention	 the	 variability	 of	 structure	 prediction	 and	 homology	
modelling	methods.	When	the	same	SHIP1cd	sequence	is	 input	 in	to	Phyre2	(Kelley	et	
al.,	 2015),	 a	 different	 template	 is	 suggested	 as	 the	 top	 scoring	 suggestion.	 The	 result	
was	 a	 model	 that	 did	 not	 contain	 the	 SHIP-specific	 extension	 known	 as	 the	 P4IM-
conating	 loop,	 because	 the	 model	 had	 skewed	 towards	 the	 arrangement	 of	 the	







the	 same	 SHIP1cd	 sequence,	 SWISS-MODEL	 and	 Phyre2	 choose	 different	 top	 scoring	
templates	to	base	the	model	on.	Both	methods	appear	to	use	very	similar	algorithms,	
but	employ	separate	self-assembled	databases	to	search	for	templates.	Although	they	








No	 structures	 of	 SHIP1cd	 are	 yet	 available,	 and	 now	 that	 this	 work	 has	 produced	 a	
suitable	 clone	 that	 provides	 soluble	 SHIP1cd	 protein,	 further	 studies	 will	 seek	 to	
crystallise	this	based	on	what	has	been	learnt	from	SHIP2cd.	This	would	hopefully	clarify	
the	 true	 structure	 of	 SHIP1cd	 and	 the	 presence	 of	 the	 P4IM-conating	 loop	 that	 is	
apparently	only	present	in	SHIP1	and	SHIP2.	Furthermore,	the	residues	responsible	for	
the	 differing	 substrate	 specificities	 between	 the	 isozymes	 may	 be	 revealed.	 Their	




in	 which	 the	 loop	 is	 closed	 over	 the	 inositide	 binding	 pocket,	 as	 suggested,	 and	 not	
stabilised	by	interaction	with	a	symmetry	related	molecule.	This	would	give	insight	into	
the	 true	 role	 of	 this	 SHIP	 specific	 loop.	 Furthermore,	 as	 SHIP1	 and	 SHIP2	 are	 clinical	
targets	for	many	diseases,	structures	with	additional	ligands	are	likely	to	provide	more	
information	 for	 a	 framework	 for	 rational	 inhibitor/drug	 design	 based	 on	 key	 ligand	
coordinating	and	catalytic	residues.	
	
Since	 the	 experiments	 performed	 in	 this	 thesis	 were	 conducted,	 the	 Potter	 group	
reported	the	structure	of	the	related	5-phosphatase	INPP5B	in	complex	with	a	second	
biphenyl	 compound,	 biphenyl	 3,3',4,4',5,5'-hexakisphosphate	 (BiPh3),	 and	 a	 complex	
with	the	simpler	compound	benzene	1,2,4,5-tetrakisphosphate	(Bz3)	(Mills	et	al.,	2016).	
INPP5B	 hydrolyses	 the	 5-phosphate	 group	 from	 water-	 and	 lipid-soluble	 signalling	
messengers.	Crystal	structures	were	resolved	to	2.89Å	with	BiPh3	and	to	2.9Å	with	Bz3;	







lipid	 head	 group	 of	 PtdIns4P	 in	 published	 INPP5B-C8-PtdIns4P	 complex	 (PDB	 3MTC)	
(Trésaugues	et	al.,	2014).	The	second	phenyl	ring	was	solvent-exposed	in	the	structure	
and	was	bound	to	the	6xhistidine	tag	of	another	INPP5B	molecule,	with	a	molecule	of	
inorganic	 phosphate	 (Pi)	 also	 present	 in	 the	 active	 site.	 The	 position	 of	 this	 Pi	 is	
interpreted	 to	 mimic	 the	 cleaved	 5-phosphate	 of	 inositol	 phosphate	 substrates	 and	
allowed	 the	 authors	 to	 identify,	 for	 the	 first	 time,	 the	 likely	 importance	 to	 catalytic	
mechanism	of	R451	which	coordinates	this	phosphate	and	an	active	site	water	molecule	




biphenyl	 polyphosphates	 are	 substrates	 for	 SHIP1	 and	 SHIP2,	 it	would	 be	 possible	 to	
construct	 mutagenesis	 experiments,	 modifying	 individual	 active	 site	 residues,	 to	 test	
the	contribution	of	R451	equivalent	in	SHIP2	(R611)	and	the	other	implicated	residues.	
This	 endeavor	 would	 be	 greatly	 assisted	 by	 hydroxyl-containing	 benzene	 and/or	
biphenyl	 polyphosphate	 standards.	 3-Hydroxy	 benzene	 1,2,4-trisphosphate	 (Bz7)	 is	
available,	 but	 a	 lack	 compounds	 are	 available	 that	 might	 represent	 the	
dephosphorylation	products	of	e.g.	Bz3,	solved	in	the	structure	of	 INPP5B	(Mills	et	al.,	
2016).	 Of	 particular	 interest	 would	 be	 2-hydroxy	 benzene	 1,4,5-trisphosphate	 (2-OH	
Bz(1,4,5)P3)	 since	Mills	 and	 coworkers	 have	 shown	 that	 in	 INPP5B	 complexes,	 the	 2-
phosphate	 of	 Bz3	 interacts	 with	 E303,	 K380	 and	 H400	 sidechains	 of	 chain	 A	 (of	 the	
asymmetric	unit)	and	shows	longer	range	interactions	with	both	N449	(3.3	Å)	and	R451	
(3.5	Å).		Due	to	the	electron	withdrawing	effect	of	the	delocalised	electrons,	a	singularly	




of	 phosphates	 from	 benzene	 phosphate	 substrates.	 Crucially,	 the	 data	 in	 chapter	 4	






Chapter	 3	 –	 Structural	 studies	 of	 Arabidopsis	 thaliana	 inositol	 1,3,4,5,6-








slime	 mould	 in	 which	 multiple	 inositol	 pentakisphosphate	 kinases	 were	 detected	
(Stephens	et	al,	1991).	Inositol	1,3,4,5,6-pentakisphosphate	(Ins(1,3,4,5,6)P5)	was	found	
to	be	 a	 prevalent	 intermediate	 above	 the	other	 IP5	 isomers	 in	 both	 animal	 and	plant	
systems.	This	observation	later	led	to	the	isolation	and	purification	of	a	inositol	1,3,4,5,6-





























Not	 long	 after,	 a	 comprehensive	biochemical	 and	 functional	 characterisation	of	 IP5	 2-
kinases	in	fission	and	budding	yeast	provided	additional	evidence	that	IPK1	encoded	an	
IP5	2-kinase	(Ives	et	al,	2000).	Many	IPK1	orthologs	across	organisms	have	been	identified	




In	 Arabidopsis	 thaliana,	 disruption	 of	 IPK1	 (AtIPK1)	 coincided	 with	 a	 loss	 in	 phytate	
without	an	accumulation	of	precursors,	therefore	reporting	a	requirement	for	AtIPK1	in	
the	later	steps	of	seed	phytate	synthesis	(Stevenson-Paulik	et	al.,	2005).	When	measured	












Further	 characterisation	 of	 AtIPK1	 and	 its	 substrate	 specificities	 was	 provided	 by	








As	 previously	 eluded	 to,	 AtIPK1	 is	 novel	 in	 its	 structural	 class	 due	 to	 being	 the	 only	

















(Gonzalez	 et	 al.,	 2010).	 An	 IP	 substrate	 is	 tightly	 bound	 in	 the	 binding	 site	 through	
interactions	 with	 all	 phosphate	 groups,	 which	 mostly	 occur	 from	 within	 the	 region	
designated	as	the	CIP-lobe	with	the	exception	of	the	phosphate	at	the	1	position	(P1)	that	






Figure	3.1	 –	Overall	 structure	of	 AtIPK1	 (taken	 from	Gonzalez	 et	 al,	 2010).	 Cartoon	 representation	 indicting	 the	
different	lobes	and	the	hinge	that	connects	them.	The	N-lobe	is	orange,	and	the	C-lobe	green	with	the	CIP	region	









in	 to	 the	 active	 site,	 site	 directed	mutagenesis	 studies	 of	 some	 of	 the	 observed	 key	
residues	 were	 carried	 out	 (Gonzalez	 et	 al,	 2010).	 Mutants	 that	 replaced	 K168,	 the	










As	noted	above,	 residues	 in	both	 the	N-	and	C-lobes	coordinate	an	 inositide	 in	 to	 the	




Mutation	 in	 R130	 results	 in	 a	 6-fold	 decrease	 in	 activity	 towards	 IP5,	 but	 as	 it	 also	
coordinates	P1	 it	 is	 not	 clear	 if	 this	 is	 a	 result	 of	 compromised	 substrate	binding	 and	
therefore	 catalytic	 function,	 or	 a	 hindrance	 from	 destruction	 of	 the	 clasp.	 It	 was	
concluded	that	mutation	in	W129	does	not	compromise	enzyme	function	and	its	role	in	












































of	essential	 ligand	binding	elements	when	compared	 to	 the	 canonical	 substrates.	Any	
resulting	structures	would	further	reveal	the	ligand	flexibility	of	AtIPK1,	and	could	provide	










































The	 optimised	 conditions	 for	 the	 crystallisation	 of	 AtIPK1-His	 had	 already	 been	








Crystals	 formed	 as	 rod	 clusters	 within	 24	 hr	 and	 were	 harvested	 in	 to	 a	 seed	 bead	
(Hampton	Research)	with	50	µL	precipitant	 to	 generate	a	 seed	 stock	 for	downstream	
microseeding.	 Using	 6	 mg/mL	 protein,	 drops	 under	 the	 same	 conditions	 were	 set	
replacing	 myo-IP6	 with	 the	 same	 concentration	 of	 the	 novel	 ligand.	 Immediately,	
approximately	0.1	µL	of	microseeding	 solution	was	added	 to	each	drop	and	 the	plate	
sealed.	Crystals	grew	as	plate	clusters	within	2-3	days	and	were	harvested	to	produce	a	
new	seed	stock.	Fresh	and	final	drops	were	set	in	the	presence	of	novel	ligand	and	again	
microseeded,	 this	 step	 being	 necessary	 to	 avoid	 the	 growth	 of	 mixed	 active	 site	




































using	 the	Wizard®	Plus	 SV	Miniprep	DNA	Purification	 System	 (Promega)	 from	an	O/N	
culture	 which	 had	 been	 inoculated	 using	 the	 Stellar	 glycerol	 stock,	 and	 grown	 in	 LB	
medium	supplemented	with	ampicillin	 (Section	2.2.6).	Once	purified,	 the	plasmid	was	
transformed	 in	 to	chemically	competent	E.	coli	Rosetta	cells	 (sections	2.2.7	&	8).	Two	
single	colonies	were	selected	to	inoculate	100	mL	cultures	in	LB	containing	0.5	%	(w/v)	
glucose	and	ampicillin	for	use	as	starter	cultures	for	the	small	scale	protein	expression	






expression	 in	 to	 inclusion	 bodies	 can	 occur,	 affecting	 the	 solubility.	 Cells	 must	 be	
harvested	by	gentle	centrifugation	and	re-suspended	in	media	without	glucose	to	allow	
IPTG	 inducible	 expression	 of	 AtIPK1-His.	 This	 step	 could	 be	 avoided	 by	 the	 use	 of	 an	















3.2.2).	 A	 high	 expression	 yield	 in	 the	 larger	 cultures	 was	 also	 observed	 under	 these	
conditions	 and	 a	 strong	 band	 the	 approximate	 size	 of	 AtIPK1-His	 (51.5	 kDa)	 can	 be	









1# 2# 3# 4#
Figure	3.3–	 SDS-PAGE	analysis	on	a	10	%	acrylamide	gel	of	 a	whole	cell	pellet	originating	 from	a	1	L	expression	












AtIPK1-His	 from	 the	 UV	 absorbance	 trace	 during	 nickel	 affinity	 purification.	 The	
overexpressed	AtIPK1-His	can	be	seen	in	fractions	15	to	21	(lanes	2-5)	but	is	negligible	in	










1# 2# 3# 4# 5# 6#










the	UV	absorbance	 trace	 corresponding	 to	 fraction	numbers	 12-16,	 samples	of	which	































excitation	wavelength	 of	 560	 nm,	 and	 emission	maxima	 at	 590	 nm.	 It	 can	 provide	 a	
quicker	and	simple	alternative	to	a	western	blot	to	confirm	the	presence	of	His-tagged	
fusion	proteins.	As	can	be	seen	in	figure	3,	AtIPK1-His	can	be	identified	with	both	staining	






























was	 eluted	 in	 the	 initial	 10	 mL	 fraction	 whilst	 the	 6xHistidine	 tag	 and	 3C	 protease	
remained	on	the	column.	The	final	10	mL	fraction	contained	some	AtIPK1-His	meaning	
the	removal	of	the	6xHistidine	tag	was	not	100	%	effective	(lane	8).	However,	this	 is	a	
trivial	 quantity	when	 compared	 to	 the	 successfully	 cleaved	 protein	 (lanes	 2-5).	 Other	
bands	 seen	 in	 lane	 8	 are	 likely	 to	 be	 the	 6xHistidine	 tag	 and	 3C	 protease.	 The	














A	 final	 size	 exclusion	 chromatography	 step	 was	 added,	 and	 performed	 as	 described	








1# 2# 3# 4# 5# 6# 7# 8#
Figure	 3.7	 –	 Immoblised	 metal	 affinity	 purification	 post-proteolytic	 cleavage	 of	 His-AtIPK1	 with	 3C	 protease.	













(Vandeput	 et	 al.,	 2007,	 Mills	 et	 al.,	 2012,	 Mills	 et	 al.,	 2016b).	 AtIPK1	 has	 also	 been	
investigated	by	the	Brearley	lab	for	binding	of	single	ring	benzene	polyphosphates,	which	




ability	 to	 coordinate	 the	 double	 ringed	 biphenyl	 polyphosphate	 compounds.	 Four	
biphenyl	 phosphate	 compounds	 were	 available	 from	 collaborators	 (Potter,	 B.V.L.;	




experience	 in	 the	 lab	 indicated	 that	 the	 tagged	 version	 of	 the	 recombinant	 protein	
resulted	in	crystals	that	diffracted	to	a	higher	resolution	when	compared	to	those	grown	
with	 AtIPK1	 protein	 that	 had	 been	 cleaved	 of	 the	 6xHistidine	 tag.	 Crystallisation	was	
achieved	 as	 described	 in	 the	 section	 3.2.4,	 using	 buffers	 and	 precipitant	 that	 had	
previously	proved	successful	in	generating	high	quality	AtIPK1-His	crystals.	This	method	









Crystals	 grew	 as	 plate	 or	 rod	 clusters,	 and	 after	 two	 to	 three	 days	 of	 growth	 were	
separated	and	individually	harvested	in	to	cryoprotectant	for	storage	in	liquid	nitrogen.	
The	 morphology	 of	 crystals	 of	 AtIPK1	 with	 biphenyl-2,3’,4,5’,6-pentakisphosphate	















3.3.4	 Crystal	 structures	 of	 AtIPK1	 with	 biphenyl	 2,3’,4,5’,6-pentakisphosphate,	 and	
biphenyl	3,3’,4,4’,5,5’-hexakisphosphate.	
	


















BiPh(2,3’,4,5’,6)P5 BiPh(3,3’,4,4’,5,5')P6Space	Group P1 P1Unit	Cella,	b,	c		(Å)α,	β,	γ	(°) 59.9,	59.8,	85.487.7,	87.7,	63.6 59.6,	59.8,	85.387.8,	88.1,	64.0Resolution	(Å) 53.6-2.18	(2.24-2.18) 53.6-2.07	(2.12-2.07)Rmerge		(%) 0.062	(0.588) 0.050	(0.495)<I/σ(I)> 8.7	(1.7) 9.3	(1.9)CC	1/2 0.991	(0.616) 0.996	(0.721)Completeness	(%) 95.31	(96.0) 96.67	(97.0)Multiplicity 2.8	(2.9) 2.9	(3.0)Wilson	B-factor 48.22 49.77












and	 P212121,	 respectively.	 However,	 similarities	 can	 be	 drawn	 upon;	 the	 refined	 P1	
AtIPK1-His	 BiPh1	 and	 AtIPK1-His	 BiPh3	 structures	 presented	 here	 also	 have	 two	
molecules	 (A	 and	 F)	 present	 in	 the	 asymmetric	 unit	 (AU),	 comparable	 to	 the	 native	
protein	in	both	binary	and	tertiary	complexes	from	the	previous	studies	(Figure	3.9	A).	
The	 observed	 P1	 space	 group	 is	 in	 agreement	 with	 all	 other	 AtIPK1-His	 structures	
generated	from	the	Brearley	lab	(unpublished	data).	
	
The	 two	AtIPK1-His	 complexes	presented	have	a	bis-tris	propane	molecule	 associated	
with	molecule	A	and	a	tris	molecule	associated	with	molecule	F.	As	this	appears	in	both	
AtIPK1-His	 structures,	 bis-tris	 propane	 is	 likely	 to	 be	 critical	 to	 crystal	 packing	 and	
stabilisation	of	the	molecules	within	the	unit	cell.	Additionally,	attempts	of	crystallisation	
without	 bis-tris	 propane,	 under	 the	 conditions	 that	 the	 González	 group	 used,	 were	
unsuccessful.	 The	 density	 for	 the	 tris	 molecule	 associated	 with	 molecule	 F	 in	 both	
structures	 is	 likely	 to	 be	 another	 bis-tris	 molecule,	 but	 it	 could	 not	 be	 confidently	
modelled	to	the	double	difference	Fourier	electron	density,	so	was	left	simply	as	a	tris	
molecule.	 Although,	 an	 argument	 can	be	made	 that	 as	 this	 occurs	 in	 both	AtIPK1-His	
structures	presented	here,	it	could	be	a	real	artifact	of	crystal	packing.	Additionally,	the	














Figure	 3.9	 –	 AtIPK1-His	 BiPh(2,3’,4,5’,6)P5	 and	 ADP	 crystal	 structure	 represented	 as	 a	 cartoon	 and	 coloured	 by	
secondary	 structure	 elements.	 (A)	 The	 two	 molecules	 in	 the	 asymmetric	 unit.	 (B)	 A	 single	 molecule	 of	 the	








Both	AtIPK1-His	 structures	present	 cross	AU	 interactions	with	neighbouring	 symmetry	
related	 molecules	 in	 the	 lattice	 via	 what	 has	 been	 term	 as	 a	 ‘fireman’s	 grip’;	 the	
6xHistidine	tag	from	molecule	A	in	the	asymmetric	unit	(AU)	‘wraps	around’	a	6xHistidine	
tag	 from	molecule	 F	 in	 a	neighbouring	AU,	appearing	 to	 stabilise	 the	 lattice	 structure	
(Figure	3.10).	Again,	this	is	in	agreement	with	other	AtIPK1-His	structure	complexes	from	
the	group	(unpublished	data)	and	is	likely	to	be	a	reason	for	the	difference	in	space	group	











The	 two	molecules	 in	 the	AU	 for	 the	AtIPK1-His	BiPh1	structure	globally	align	 to	each	
other	with	a	RMSD	of	0.341,	and	the	active	site	residues	0.176.	The	near	equivalence	can	
be	seen	 for	 the	AtIPK1-His	BiPh3	structure	where	 the	respective	alignment	 results	are	










discussed	 later,	 it	 has	 undergone	 large	 conformational	 changes	 to	 accommodate	 the	
novel	ligands.	This	may	result	in	differences	between	the	two	molecules	in	the	AU	during	




























This	 is	 likely	 to	be	explained	by	 the	differing	numbers	of	phosphates	and	 their	 spatial	
positioning	on	the	phenyl	rings,	as	well	as	the	relative	planes	of	each	ring	in	the	molecule.	
The	rings	of	BiPh3	are	planar	with	respect	to	one	another,	and	slightly	rotated	in	BiPh1.	




















Analysis	 of	 hydrogen	 bonding	 and	 hydrophobic	 interactions	 was	 achieved	 using	 the	
LigPlot+	 program	 (Laskowski	 &	 Swindells,	 2011),	 which	 automatically	 generates	
schematic	diagrams	of	protein-ligand	interactions	based	on	the	distances	between	atoms	
in	a	given	PDB	file	(Figure	3.12).	This	revealed	that	both	compounds	are	coordinated	by	
K200,	 K170,	 N238	 &	 K168,	 suggesting	 that	 these	 residues	 are	 likely	 to	 be	 critical	 to	














by	 K411	 and	 R415,	 both	 of	 which	 form	 interactions	 with	 the	 P4	 phosphate	 on	 the	
canonical	inositol	phosphate	substrate.	It	seems	that	most	interactions	that	coordinate	
the	ligand	in	the	active	site	occur	on	the	“lower”	ring	of	the	biphenyl	compounds,	with	















significantly	 alter	 the	 overall	 conformation	 of	 the	 AtIPK1.	 Additionally,	 there	 are	 no	
significant	domain	movements	and	the	active	site	features	such	as	the	G-loop,	L3	and	α6	
overlay	closely	(see	section	3.1).	There	is	a	small	difference	in	the	positioning	of	one	of	









































3.13).	 Two	 of	 these	 have	 already	 been	 discussed	 above	 and	 occupy	 the	 P1	 and	 P6	
positions	 of	 a	 bound	myo-IP5	 or	 IP6.	 The	 additional	 alignment	 of	 phosphates	 occurs	
between	 P4	 of	 BiPh1	 and	 P3	 of	 BiPh3	 on	 the	 upper	 rings	 of	 both	 compounds.	 These	
phosphates	 appear	 to	 have	 no	 hydrogen	 bonding	 interactions	 with	 AtIPK1.However,	
nearby	hydrophobic	contacts	with	G19	and	G20	occur	with	both	ligands.	This	may	not	be	
an	 important	 artifact	 of	 anchoring	 a	 substrate	 in	 to	 the	 active	 site	 given	 the	 lack	 of	
hydrogen	 bonding	 between	 the	 protein	 and	 ligand	 in	 this	 region,	 but	 it	may	 provide	












(unpublished	data),	 results	 in	RMSD	values	of	0.760	and	0.780,	 respectively.	Providing	
evidence	 that	 significant	 conformational	 changes	 are	 likely	 to	 have	 taken	 place	 to	
accommodate	the	novel	ligands.	These	changes	are	isolated	to	the	N-lobe	of	the	protein	















































and	 BiPh3	 (Figure	 3.14),	 it	 is	 apparent	 that	 fewer	 interactions	 anchor	 the	 biphenyl	





C-lobe	 in	both	 structures,	which	unlike	 the	N-lobe,	 has	not	undergone	any	 significant	
conformational	 changes	upon	binding	 the	biphenyl	 compounds.	Not	only	 are	 the	 two	
biphenyl	compounds	in	very	altered	orientations	when	compared	to	one	another;	they	
bind	 in	 an	 almost	 orthogonally	 to	myo-IP6,	 which	 provides	 explanation	 for	 the	 large	
movement	of	the	N-lobe	upon	biphenyl	binding.		
	


















for	 both	 BiPh1	 and	 BiPh3.	 This	 is	 perhaps	 not	 entirely	 unexpected	 due	 to	 the	 vast	
differences	 in	 structure	 between	 myo-IP6	 and	 the	 biphenyl	 compounds,	 making	 it	
impossible	 to	accommodate	a	phosphate	 in	 the	 ‘inositol’	 P2	binding	pocket.	 This	 also	
offers	explanation	for	the	lack	of	interactions	between	the	compound,	magnesium	ions	







ligand,	 evidence	 of	 this	 can	 also	 be	 seen	 in	 structures	 with	 benzene	 phosphate	
compounds	(H.	Whitfield,	UEA,	unpublished)	which	are	discussed	in	due	course.	
	
The	 structures	 of	 the	 same	 recombinant	 AtIPK1-His	 protein	 in	 complex	 with	 three	
benzene	polyphosphate	substrate	mimics,	and	ADP,	have	previously	been	solved	by	a	
colleague	 (H.	 Whitfield,	 UEA,	 unpublished).	 These	 were	 benzene	 1,2,3,4-
tetrakisphosphate	(Bz1),	benzene	1,2,3,5-tetrakisphosphate	(Bz2),	and	benzene	1,2,4,5-
tetrakisphosphate	 (Bz3).	 The	 structure	 with	 Bz3	 represents	 the	 highest	 resolution	
structure	with	 these	compounds	 (1.90	Å),	of	which	 the	alignment	with	 the	AtIPK1-His	
BiPh1	and	AtIPK1-His	BiPh3	structures	can	be	seen	in	Figure	3.54.	As	these	mimics	closer	
represent	physiological	 ligands	due	to	their	single	ring	structure,	 it	 is	unsurprising	that	





























































L3	and	the	G-loop	are	different	 to	those	 in	 the	AtIPK1-His	Bz3	and	AtIPK1-His	myo-IP6	
complexes.	 The	 origins	 of	 the	 conformational	 changes	 that	 accommodate	 a	 biphenyl	
polyphosphate	are	discussed	in	more	detail	in	section	3.2.4.	
	
Again,	 in	 the	 AtIPK1-His	 Bz3	 structure,	 the	 ‘inositol’	 P6	 and	 P1	 binding	 pockets	 are	
occupied	 just	 like	 all	 the	 previous	 structures	 discussed,	 but	 with	 P2	 and	 P1	 of	 Bz3,	
























































especially	 when	 comparing	 the	 location	 of	 the	 Bz3	 phosphate	 at	 this	 position	 to	 the	











rings,	 P4	and	P3	 respectively.	 There	 is	 no	hydrogen	bonding	 to	 these	phosphates	but	




















together	with	 structures	 have	 revealed	 that	 it	 possesses	 three	 distinct	 conformations	
when	in	 its	apo-form,	and	inositide	and/or	nucleotide	bound	forms	(Baños-Sanz	et	al.,	
2012(Gosein	et	al.,	2012)).	As	mentioned	in	section	3.3.3,	residues	in	both	the	N-	and	C-
lobes	 coordinate	an	 inositide	 in	 to	 the	active	 site,	which	consequently	brings	 the	 two	
lobes	 together,	 this	has	been	 termed	 the	 “closed	 form”	of	 the	protein	 (Figure	3.17	&	









































the	 inositide	 binding	 site.	 Additionally,	 the	 clasp	 observed	 in	 the	 closed-form	 is	 not	
formed	and	L3	remains	flexible,	and	α6	disordered.	These	elements	are	only	fully	formed	
in	the	closed-form	where	L3	is	also	forming	a	“lid”	that	closes	over	the	active	site	pocket.	
When	superimposing	all	 three	of	 these	conformational	states	 to	AtIPK1-His	BiPh1	and	
AtIPK1-His	BiPh3,	it	becomes	apparent	that	both	structures	are	akin	to	this	half-closed	
form	(Figure	3.17	&	3.18).	They	align	with	an	RMSD	of	0.510	and	0.424,	respectively,	a	
result	 which	 is	 perhaps	 surprising	 given	 that	 they	 are	 ternary	 complexes	 with	 both	






































interaction	with	a	 ligand	and	 therefore	 L3.	 In	absence	of	 clasp	 formation,	 the	protein	
remains	in	the	half-closed	form	when	accommodating	a	biphenyl	polyphosphate	rather	
than	 transitioning	 to	 the	 closed	 form.	 The	 greater	 size	 (volume)	 of	 the	 biphenyl	















conformational	 states	 representing	 different	 stages	 of	 the	 catalytic	 cycle	 of	AtIPK1.	A	
‘closed’	conformation	was	first	described	for	native	protein	with	inositide	and	cofactor	
bound	 (Gonzalez	 et	 al.,	 2010).	 Subsequent	 work	 with	 a	 W129A	 mutant	 allowed	
identification	of	the	apo-form	in	‘open’	conformation	and	‘half-closed’	nucleotide-bound	








activation.	 Of	 the	 protein	 residues	 involved	 in	 substrate	 recognition	 and	 enzyme	
activation,	 the	 authors	 concluded	 that	 R130,	 K170	 and	 K411	were	 critical	 to	 enzyme	

















Here	 crystal	 structures	 of	 AtIPK1	 were	 obtained	 in	 ternary	 complex	 with	
BiPh(2,3’,4,5’,6)P5	(BiPh1)	or	BiPh(3,3’,4,4’,5,5’)P6	(Biph3)	and	ADP.	The	data	clearly	show	





2013)	 reveals	 the	major	 contribution	 of	 residues	 that	 coordinate	 the	 6-phosphate	 of	






Evidently,	 successful	 future	 crystallographic	 studies	 of	 AtIPK1	with	 the	 two	 additional	
biphenyl	compounds	presented	here,	BiPh2	&	BiPh4	(Table	1.2),	would	provide	further	
evidence	of	the	essential	features	in	ligand	binding	and	catalysis.	Following	this	up	with	
mutagenic	 studies,	 especially	 of	 those	 residues	 coordinating	 the	 P1	 position,	 could	













Chapter	 4	 –	Novel	 fluorescent	 properties	 of	 the	 benzene-	 and	 biphenyl-	






study	 of	 the	 enzymes	 related	 to	 PI3K/Akt	 signalling,	 PtdIns(1,4,5)P3	 3-kinases	 and	
PtdIns(1,4,5)P3	 5-phosphatases.	 The	 utility	 and	 versatility	 of	 the	 BzPs	 prompted	 the	
synthesis	 of	 a	 second	 set	 of	 related	 derivatives	 that	 also	 act	 as	 inositol	 phosphate	
mimics,	 the	 biphenyl	 polyphosphates	 (BiPhs),	 also	 discussed	 in	 section	 1.1.3.	 Just	 like	





PKBα	 PH-domain,	 and	 type	 II	 inositol	 polyphosphate	 5-phosphatase	 (INPP5B)	 with	

















This	 chapter	 discusses	 the	use	of	 a	 set	 of	 fluorescently	 tagged	 inositol	 phosphates	 as	
probes	 for	 use	 in	 fluorescence	 polarisation	 binding	 assays	 to	 investigate	 the	 binding	
affinities	of	SHIP1cd,	SHIP2cd	and	AtIPK1	for	various	ligands	and	inhibitors	(see	table	4.1	





N-terminus	 of	 IP3	 receptors,	 which	 are	 intracellular	 Ca2+	 channels	 (Ding	 et	 al.,	 2010).	
Another	 study	 has	 used	 IP5	 conjugated	 at	 the	 2-position	 with	 5-carboxyfluorescein	
(FAM)	 to	yield	2-FAM-IP5,	 the	probe	utilised	most	 frequently	 in	 this	work	 (Riley	et	al.,	
2014).	It	was	used	to	visualise	the	internal	visualisation	of	inositol	phosphates	by	H1229	













fluorescence	 lifetime,	 60%	 of	 the	 emitted	 light	 will	 be	 detected	 in	 the	 plane	 of	 the	
exciting	 light,	 and	 the	 anisotropy	will	 be	 0.4.	 The	 relationship	 between	 anisotropy	 (r)	
and	the	angle	(q)	of	an	oriented	fluorophore	is	shown	by	equation	4.1.	
	




1.	 If	 the	 molecule	 rotates	 during	 its	 fluorescence	 lifetime,	 less	 emitted	 light	 will	 be	
aligned	with	the	excitation	plane,	and	r	will	be	<	0.4.	Anisotropy	measurements	reveal	
the	average	angular	displacement	of	 the	 fluorophore	 that	occurs	between	absorption	
and	emission	of	a	photon.	The	 rate	of	 tumbling	 is	 inversely	proportional	 to	molecular	
volume,	therefore	binding	of	a	small	fluorescent	probe	to	a	much	larger	protein	would	
increase	 anisotropy.	 FP	 measures	 this	 change	 in	 anisotropy	 as	 a	 fluorescent	 ligand	
binds.	 It	 thereby	allows	non-destructive	quantification	of	binding	without	 the	need	 to	
separate	bound	 from	 free	 ligand,	 and	 is	 calculated	using	 equation	4.2.	 It	 is	 useful	 for	
measurement	 of	 low-affinity	 interactions	 in	 which	 rapid	 ligand	 dissociation	 during	
separation	of	bound	and	free	ligand	compromises	analysis.	Additional	advantages	of	FP	
include	 the	 opportunity	 to	 make	 many	 measurements	 from	 the	 same	 sample	 under	






































Using	 a	 Hidex	 Sense	 multimodal	 microplate	 reader,	 and	 in	 a	 384	 well	 Corning	 low	
volume	black	flat	bottomed	polystyrene	plate,	finite	fluorescence	intensity	readings	of	
100	µM	benzene-	and	biphenyl-	phosphates	in	20	mM	HEPES	pH	7.3,	1	mM	MgCl2	were	
taken.	For	 the	excitation,	 filters	used	were;	265±25,	280±10,	and	289±10	nm.	And	 for	
emission,	340±80	nm.	Well	volume	was	20	µL.	
	








Biphenyl	 phosphates	 and	 their	 reaction	 products	 from	 reaction	 with	 SHIP2cd	 were	
separated	 by	 anion	 exchange	 chromatography	 on	 a	 2mm	 x	 250	 mm	 IonPac	 AS11	
column,	with	2	mm	x	50	mm	AG11	guard	column,	eluted	with	NaOH.	The	column	was	
eluted	at	a	flow	rate	of	0.5	mL	/	min	according	to	the	following	gradient:	time	(min),	%	B	








excitation/band	 width;	 330/10	 nm	 emission/bandwidth	 and	 gain	 (photomultiplier	







immediately,	 then	 after	 incubation	 at	 37	 °C	 	 for;	 15,	 30,	 60	 and	 120	 min.	 Before	
injection,	 samples	 were	 diluted	 to	 0.2	 µM	 biphenyl	 phosphate	 with	 analytical	 grade	
water	and	boiled	for	1	min	to	terminate	the	reaction.	
	




(225	mM	NaOH);	 0,0;	 20,100;	 21,0;	 30,	 0.	 Samples	 (50	 µL	 volume)	 were	 injected	 by	
Jasco	 AS-950	 autosampler	 and	 peaks	 were	 monitored	 either	 at	 265/10	 nm	
excitation/band	 width;	 340/10	 nm	 emission/bandwidth;	 or	 285/10	 nm	




A	 Corning	 96	 well	 half-area	 black	 polystyrene	 flat	 bottom	 plate	 was	 used	 with	 a	














in	 20	 mM	 HEPES	 pH	 7.3	 1mM	 MgCl2,	 was	 incubated	 with	 increasing	 protein	
concentrations	(up	to	2.5	µM).	Aliquots	(20	µL)	were	dispensed	 in	quadruplicate	wells	
and	 polarisation	 of	 the	 probe	 was	 measured	 at	 25°C.	 All	 data	 was	 averaged	 and	
analysed	by	a	4-parameter	fit	using	GraphPad	Prism	6	software	allowing	dose-response	
curves	to	be	constructed	and	EC50	values	to	be	obtained.	
Similarly,	 for	 inhibition	 assays,	 inhibitor	 (10	 nM-100	µM)	was	 titrated	 against	 AtIPK1,	













4.3.1	 UV	 absorbance	 and	 fluorescence	 properties	 of	 the	 biphenyl	 and	 benzene	
polyphosphates	
As	 discussed	 previously	 (section	 1.1.3	 &	 4.1.1),	 benzene	 1,2,4,5-tetrakisphosphate	
(Bz(1,2,4,5)P4	 /	 Bz3)	was	 designed,	 along	with	 six	 additional	 benzene	 polyphosphates	
and	four	biphenyl	polyphosphates,	as	a	simple	 inositol	phosphate	analogue	which	can	
been	exploited	as	novel	ligand	and	inhibitor	of	inositol	phosphate	metabolising	enzymes	
(Mills	et	al.,	2008).	 In	a	previous	assay	which	 followed	 the	conformational	 changes	of	
AtIPK1	by	monitoring	 its	 intrinsic	tryptophan	fluorescence	upon	ligand	binding	(results	
not	shown),	 it	became	apparent	 that	Bz3	exhibited	 its	own	fluorescence	properties	at	
similar	excitation	and	emission	wavelengths	to	tryptophan.	Before	further	exploring	the	
fluorescence	properties	of	 this	 inositol	phosphate	mimic,	 it	was	deemed	necessary	 to	
























































stronger	 UV	 absorption	 properties	 between	 250	 –	 330	 nm	 than	 the	 benzene	
polyphosphates	(Figure	4.1).	All	the	compounds	displayed	distinctive	profiles	with	clear	
differences	 in	 absorption	 maxima.	 Some	 compounds	 showed	 very	 weak	 absorption	
between	these	wavelengths,	with	biphenyl	2,3’,4,5’,6-pentakisphosphate	(BiPh1)	being	
the	weakest	 absorbing	 of	 the	 biphenyl	 phosphates,	 exhibiting	 no	 obvious	 peak	 in	 its	
absorbance	 spectra	 (Figure	 4.1	 -A).	However,	 it	 is	 evident	 that	 BiPh1	displays	 a	 small	
absorption	peak	around	250	nm.	Biphenyl	3,3’,4,4’,5,5’-hexakisphsphate	(BiPh3)	has	the	
highest	 absorbance	 between	 these	wavelengths	with	 a	 peak	maxima	 at	 266	 nm.	 For	
biphenyl	 2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2)	 and	 6,6’-difluorobiphenyl	 3,3’,4,4’-







differences	 in	 their	 spectra;	 benzene	 1,2,4-trisphosphate	 (Bz(1,2,4)P3	 /	 Bz5)	 has	 the	
highest	absorbance	of	 the	benzene	phosphates	with	a	strong	absorbance	peak	at	275	
nm,	 whereas	 others	 such	 as	 Bz3	 are	 far	 less	 UV	 absorbent	 and	 have	 differing	
absorbance	maxima	(Figure	4.1	-B).	An	absorbance	peak	for	Bz3	occurs	at	279	nm.	Many	
have	higher	absorbance	at	260	nm,	but	this	is	common	to	the	absorbance	spectra	of	all	











As	 the	 majority	 of	 the	 biphenyl	 polyphosphates	 displayed	 large	 peaks	 in	 their	 UV	




agreeably	 showed	 that	 the	 BiPh’s	 did	 indeed	 possess	 fluorescent	 properties	 and	 the	
most	 appropriate	 emission	 wavelength	 to	 utilise	 this	 was	 340	 nm.	 After	 fixing	 the	










































In	 a	 different	 manner	 using	 a	 fluorimeter	 and	 quartz	 cuvette	 method,	 involving	





wide	 in	 nature	 and	 span	 a	 broad	 range	 of	 wavelengths,	 therefore	 expanding	 the	















































Figure	 4.3	 –	 Fluorescence	 wave	 scans	 of	 100	 μM	 benzene	 polyphosphate	 (A)	 Excitation	 spectra	 at	 a	 fixed	 an	









4.3,	 and	 provides	 a	 more	 direct	 comparison	 to	 the	 BiPh’s	 (Figure	 4.4).	 Investigation	
under	 this	method	using	discreet	 filter	 sets	 at	 fixed	wavelengths	 revealed	 that	 unlike	
the	 BiPh’s,	 Bz3	 and	 Bz5	 exhibited	 low	 fluorescence	 intensities	 at	 an	 excitation	
































Figure	 4.4	 -	 Fluorescence	 properties	 of	 100	 μM	 benzene	 polyphosphates.	 Intensity	 readings	 at	 a	 fixed	 emission	
wavelength	of	340	nm.	Values	are	corrected	against	the	background	signal	from	the	buffer.	Only	benzene	1,2,4,5-







Currently,	 only	 empirical	 observations	 can	 be	 made	 when	 considering	 why	 these	
compounds	are	fluorescent.	As	has	been	seen,	some	are	more	fluorescent	than	others,	
which	 can	 likely	 be	 attributed	 to	 the	 different	 positioning	 of	 the	 phosphate	 groups	
around	the	benzene	rings.	Looking	forward,	efforts	are	focussing	on	collaboration	with	
physical	computational	chemists	to	elucidate	the	features	of	these	compounds	that	give	
them	 these	 unique	 spectral	 properties.	 Eventually,	 this	 may	 shed	 light	 on	 which	
hypothetical	 products	 of	 the	 turnover	 of	 these	 compounds	 would	 also	 have	 UV	 and	
fluorescent	properties	and	 in	 turn	would	hopefully	allow	them	to	be	 identified	during	
assays.	
	
Despite	 having	 been	 widely	 utilised	 as	 simple	 inositol	 polyphosphate	 surrogates	 in	
inhibition	and	structural	studies	(Mills	et	al.,	2008,	Mills	et	al.,	2012,	Mills	et	al.,	2016),	
formally	the	spectral	properties	of	these	compounds	have	been	left	undiscovered	until	
recently	 and	 these	 results	 are	 yet	 to	 be	 published.	 The	 unearthing	 of	 these	 novel	
properties	opens	up	new	opportunities	to	exploit	these	compounds	in	enzymatic	assays,	









As	 widely	 introduced	 previously,	 the	 biphenyl	 phosphates	 have	 been	 reported	 as	
inhibitors	of	the	inositol	polyphosphate	5-phosphatases,	including	SHIP2	for	which	there	
is	 also	 an	 available	 structure	 of	 the	 complex	 formed	 with	 biphenyl	 2,3’,4,5’,6-
tetrakisposphate	 (BiPh1)	 (Mills	 et	 al.,	 2012).	 Currently	 there	 has	 been	 no	 reports	 of	
BiPhs	as	substrates	against	the	proteins	that	have	been	demonstrated	to	accommodate	
them	 in	 their	 active	 sites.	 Characterisation	 solely	 as	 inhibitors	 of	 inositol	 phosphate	
phosphatases	has	been	described	with	no	reports	testing	for	catalytic	activity.	However,	
3-hydroxybenzene	 1,2,4-trisphosphate	 (Bz7)	 is	 an	 example	 of	 a	 simpler	 single	 ringed	
inositol	 phosphate	mimic	 (Table	1.1)	 that	has	been	 reported	as	 a	 substrate	 for	 type	 I	




As	 a	 preliminary	 assay	 to	 investigate	 if	 the	 biphenyl	 polyphosphates	 could	 indeed	 be	
substrates	 of	 SHIP1	 and	 SHIP2,	 SHIP2cd	 protein	 was	 incubated	 with	 biphenyl	
2,2’,4,4’,5,5’-hexakisphosphate	 (BiPh2)	 and	 biphenyl	 3,3’,4,4’,5,5’-hexakisphosphate	
(BiPh3)	overnight,	and	the	products	analysed	by	 ion	exchange	chromatography.	Three	
detection	 methods	 in	 series	 were	 used	 visualise	 the	 disappearance	 of	 BiPh2,	 and	 to	
monitor	 to	 the	 appearance	 of	 any	 products	 of	 the	 reaction	 which	 may	 or	 may	 not	
exhibit	 spectral	 properties	 like	 the	 parent	 compound.	 Despite	 using	UV,	 fluorescence	











225	mM	NaOH	 over	 20	min.	 Detection	 of	 BiPh2,	 in	 Figure	 4.5	 –	 A,	 was	 achieved	 by	
monitoring	 the	UV	absorbance	of	 the	column	eluent	at	270	nm.	 In	 the	overlay	of	 the	
reactions,	a	peak	of	UV	absorbing	material	can	be	seen	eluting	at	approximately	14	min,	
which	 has	 then	 disappeared	 after	 overnight	 incubation	 with	 SHIP2cd.	 This	 peak	 was	
confirmed	 as	 that	 of	 BiPh2	 by	 spiking	 the	 sample	 with	 a	 standard	 of	 BiPh2.	 The	
disappearance	of	BiPh2	 is	accompanied	by	 the	appearance	of	a	 series	of	peaks	of	UV	
absorbance	 eluting	 between	 5	 and	 12	 min,	 and	 an	 additional	 peak	 eluting	 after	 the	





































































column	 eluent	 at	 excitation	 of	 270	 nm	 and	 emission	 330	 nm,	 and	 produces	 a	much	
clearer	trace	(Figure	4.5	-	B).	A	fluorescence	peak	of	BiPh2	can	be	seen	at	approximately	
14	min,	 in	agreement	with	the	UV	trace,	and	again	 is	completely	diminished	after	 the	
overnight	 incubation.	 The	 appearance	 of	 new	 fluorescence	 peaks	 after	 incubation	 is	
observed	but	none	appear	to	elute	in	clear	agreement	with	the	UV	absorbing	peaks	in	
panel	 A.	 This	 suggests	 that	 some	 detectable	 products	 from	 the	 dephosphorylation	 of	
BiPh2	maintain	UV	properties,	but	lose	fluorescent	properties	at	these	wavelengths.	Or	
alternatively,	display	weak	UV	absorption	but	remain	detectable	by	fluorescence,	these	
properties	 are	 observed	 with	 with	 Bz3	 (Figure	 4.1	 &	 4.3).	 Again,	 in	 the	 absence	 of	
metabolites	of	BiPh2	by	SHIP2	 it	 is	unclear	what	 the	products	could	be	and	 therefore	
why	 they	 wouldn’t	 exhibit	 fluorescent	 properties.	 Investigations	 are	 hindered	 by	 the	
lack	of	information	about	which	and	how	many	phosphates	are	being	removed.	
	
Panel	 C	 of	 Figure	 4.5	 Shows	 the	 detection	 of	 reaction	 products	 monitored	 by	
suppressed	 ion	 conductivity.	 The	 steep	 gradient	 of	 the	 baseline	 is	 a	 result	 of	 the	
increased	conductivity	by	 the	gradient	of	 the	NaOH	solvent;	 therefore	 it	 is	not	wholly	
suppressed.	Again	a	peak	was	detected	at	approximately	14	min	and	had	disappeared	
after	 overnight	 incubation,	 supporting	 the	 turnover	 of	 BiPh2	 by	 SHIP2.	 A	 peak	 at	
approximately	6.5	min	 increased	 in	area	after	overnight	 incubation	with	SHIP2cd,	and	
corresponds	to	an	accumulation	of	inorganic	phosphate,	likely	liberated	from	BiPh2.		
	
Under	 the	 same	 conditions,	 the	 assay	 was	 carried	 out	 with	 an	 additional	 biphenyl	
polyphosphate;	BiPh3,	and	analysed	by	the	same	anion	exchange	method	(Figure	4.6).	
With	 all	 three	 detection	methods,	 the	 peak	 corresponding	 to	 BiPh3	 had	 disappeared	
after	the	overnight	incubation.	The	peaks	were	detected	at	the	same	retention	time	as	
BiPh2,	perhaps	not	surprising	as	they	possess	the	same	number	of	phosphates,	albeit	in	












































































these	methods,	 it	 can	 still	 be	assumed	 that	BiPh3	 is	 a	 substrate	 for	 SHIP2	due	 to	 the	
observed	loss	of	the	UV,	fluorescence	and	conductivity	peaks.	Additionally,	the	area	of	









for	monitoring	 the	biphenyl	polyphosphates,	 further	 investigations	 in	 to	 the	BiPh’s	 as	
substrates	 of	 both	 SHIP1cd	 and	 SHIP2cd	were	 performed	 based	 on	 this	 fluorescence	
method.	Assays	were	set	up	with	either	SHIP1cd	or	SHIP2cd,	and	with	each	of	the	four	
available	 biphenyl	 compounds.	 The	 reactions	were	 stopped	 at	 distinct	 time	points	 by	
diluting	and	boiling	the	sample	for	1	min,	before	injection	on	to	an	ion	exchange	column	
for	analysis.	The	two	assays	presented	in	Figure	4.7	&	4.8	represent	the	most	efficient	
turnover	 of	 a	 biphenyl	 polyphosphate	 by	 each	 of	 these	 enzymes,	 as	 summarised	 in	
figure	4.9	and	discussed	in	due	course.	
	
Figure	 4.7	 shows	 the	 disappearance	 of	 a	 fluorescence	 peak	 of	 BiPh2	 eluting	 at	


































































































































































that	 the	 two	 isozymes	 may	 have	 differing	 substrate	 specificities	 (Figure	 4.9).	 Overall	
SHIP1cd	was	more	active	towards	these	substrate	mimics	than	SHIP2cd,	where	all	four	
compounds	were	hydrolysed	by	at	least	60	%	on	completion	of	the	assay.	In	the	case	of	
SHIP2cd,	 only	 the	 reaction	with	 BiPh2	 progressed	 to	 this	 extent.	 No	 enzyme	 kinetics	
parameters	 can	 be	 drawn	 from	 these	 investigations	 as	 only	 single	 concentrations	 of	










































































of	 these	proteins	by	means	of	end-point	 reactions,	but	being	able	 to	 follow	turn-over	
and	subsequent	 loss	 in	 fluorescence	 in	real-time	assays	would	offer	 further	utility	and	
convenience	 to	 investigate	 these	 enzymes,	 and	 perhaps	 other	 inositol	 polyphosphate	
phosphatases	beyond	just	SHIP1	and	SHIP2.		
	
Assays	 of	 SHIP2cd	 and	 the	 BiPh’s	 were	 performed	 in	 96-well	 black	 plates,	 with	 the	
reaction	being	 instigated	by	 the	addition	of	a	 fixed	concentration	of	SHIP2cd.	Despite	
extensive	efforts	to	collect	full	sets	of	data,	by	fine-tuning	the	method	and	making	use	
of	 numerous	 plate	 readers,	 only	 preliminary	 data	 was	 obtained.	 This	 type	 of	
instrumentation	 is	 generally	 considered	 less	 sensitive	 when	 monitoring	 fluorescence	
than	detectors	that	are	employed	with	HPLC	and	IC	systems,	which	made	it	challenging	
to	 gain	 consistent	 results	 with	 this	 method.	 Other	 parameters	 such	 as	 temperature	
were	 also	 limiting	 factors.	 Nevertheless,	 Figure	 4.10	 shows	 the	 outcome	 of	 an	 assay	
between	 SHIP2cd	 and	 BiPh3.	Where	 BiPh3	was	 chosen	 specifically	 due	 to	 having	 the	
strongest	fluorescence	characteristics	of	the	BiPhs,	thus	minimising	the	problems	with	























































4.3.3	 Using	 fluorescently	 tagged	 inositol	 phosphates	 to	 explore	 ligand	 binding	 by	
fluorescence	polarisation	
A	 selection	 of	 fluorescently	 tagged	 inositol	 polyphosphates	 were	 obtained	 from	
collaborators	 (Potter,	 B.V.L.;	 University	 of	 Bath,	 UK)	 and	 were	 utilised	 in	 creating	
binding	 curves	 with	 SHIP1cd,	 SHIP2cd	 and	 AtIPK1	 via	 a	 fluorescence	 polarisation	
method	 (section	 4.1	 &	 4.2.).	 The	 curves	 are	 constructed	 by	 titration	 of	 increasing	
concentrations	 of	 protein	 to	 a	 fixed	 concentration	 of	 fluorescent	 probe	 while	
monitoring	 the	 emissions	 in	 the	 perpendicular	 and	 parallel	 channels	 relative	 to	 the	
polarised	excitation	channel.	The	method	is	very	robust	and	reproducible,	and	offers	a	
high-through	put	means	 of	 conducting	 these	 types	 of	 investigations	 because	multiple	
data	sets	can	be	analysed	at	any	one	time	in	384-well	microtiter	plates.	
	
An	 EC50	 is	 related	 to	 but	 not	 equivalent	 to	 the	 disassociation	 constant	 (Kd),	 and	 is	
defined	 simply	 as	 the	 effective	 concentration	 of	 agonist	 that	 that	 provokes	 a	 half	
maximal	response;	the	concentration	required	to	bring	the	curve	to	a	half	way	point	(50	
%)	between	the	bottom	and	top	plateaus	of	the	dose-response	curve(0	and	100	%).	It	is	





400	 mP.	 However	 these	 values	 are	 often	 not	 the	 experimental	 plateaus,	 this	 is	
recalculated	and	accounted	for	when	fitting	a	four	parameter	fit	to	the	dose-response	
curves,	which	actually	provides	what	is	referred	to	as	the	relative	EC50	but	the	adjective	
relative	 is	 usually	 omitted.	 The	 binding	 of	 SHIP2cd	 and	 AtIPK1	 to	 all	 the	 available	
















































Binding	 curves	 and	 resulting	 EC50	 values	 for	 all	 three	proteins	with	 2-FAM-IP5,	which	








Figure	 4.11	 –	 Dose-response	 binding	 curves	 of;	 (A)	 AtIPK1,	 (B)	 SHIP1cd	 &	 (C)	 SHIP2cd	 to	 2-FAM-IP5.	 Binding	 is	
monitored	by	the	change	in	polarisation	of	2-FAM-IP5	upon	increased	concentration	of	protein,	λex	=	485,	λem	=	520.		








































































complex	 with	 the	 fluorescent	 tagged	 inositol	 phosphates	 therefore,	 though	 likely,	 it	
cannot	 be	 confirmed	 that	 they	 are	 binding	 in	 the	 active	 sites.	 Despite	 this,	 evidence	
from	 the	 displacement	 of	 these	 polarisation	 probes	 from	 SHIP1cd	 and	 SHIP2cd	 by	
traditional	substrates	suggests	that	they	do	indeed	bind	in	the	active	site	(Figure	4.12).	





slopes.	 Just	 like	 the	 EC50	 is	 related	 to	 Kd,	 the	 IC50	 is	 also	 indirectly	 related	 to	 the	
inhibition	 constant	 (Ki)	 and	 can	 be	 arrived	 at	 via	 use	 of	 the	 Cheng-Prusoff	 equation	
(Cheng	and	Prusoff,	1973).	
	
For	 both	 proteins,	 Ins(1,3,4,5,6)P5	 (IP5)	 displaced	 2-FAM-IP5	 more	 effectively	 than	





the	 resulting	 IC50	 is	 ambiguous	with	 a	 wide	 confidence	 interval.	 However,	 the	 value	











Figure	 4.12	 –	 Inhibition	 curves;	 Displacement	 of	 2-FAM-IP5	 by	 inositol	 1,3,4,5-tetrakisphosphate	 and	 inositol	
1,3,4,5,6-pentakisphosphate	from	(A)	SHIP1cd	&	(B)	SHIP2cd.	IC50	values	are	shown	in	black	for	displacement	with	
IP4	and	grey	for	IP5.	















































2-FAM-IP5	 from	 the	 active	 sites	 of	 AtIPK1,	 SHIP1cd	 and	 SHIP2cd,	 at	 fixed	 probe	 and	
protein	 concentrations	of	 2	 and	200	nM.	As	 an	example	of	 the	data	obtained,	 Figure	













































































It	 is	 inherent	 in	 the	 interpretation	 of	 experiments	 performed	 in	 this	 and	 subsequent	
sections	 that	 2-FAM-IP5	 is	 an	 active	 site	 ligand	 of	 the	 proteins	 tested.	 For	 AtIPK1,	
chapter	3	provides	categorical	structural	data	showing	the	biphenyl	phosphates	ligands	
co-ordinate	 inositol	 phosphate-coordinating	 residues	 in	 the	 active	 site	 of	 AtIPK1.	
Furthermore,	 structures	 of	 SHIP2	 and	 an	 additional	 inositol	 5-phosphatase,	 INPP5B,	
show	 these	 surrogate	 ligands	 in	 the	 active	 site	 pocket	 coordinated	 by	 residues	 that	
interact	with	 P4	 of	 a	 canonical	 substrate	 (Mills	 et	 al.,	 2012,	Mills	 et	 al.,	 2016).	 Given	
displacement	occurs	in	all	three	proteins	it	 is	 likely	that	2-FAM-IP5	is	 indeed	binding	in	
the	 active	 site.	 Additionally,	 bona	 fide	 substrates	 were	 able	 to	 displace	 2-FAM-IP5	
(Figure	 4.12),	 inositol	 phosphates	 have	 not	 been	 shown	 to	 bind	 to	 these	 types	 of	
proteins	elsewhere	other	than	the	active	site.	
	
Despite	 high	 through	 put	 screening,	 SHIP2cd	 in	 complex	 with	 2-FAM-IP5	 failed	 to	
produce	 crystals,	 and	 due	 to	 time	 constraints	 SHIP1cd	 has	 not	 yet	 been	 subjected	 to	
crystallisation	screening.	Attempts	to	solve	crystal	structures	of	2-FAM-IP5	/	AtIPK1	did	
not	 resolve	 electron	 density	 that	 could	 be	 unambiguously	 assigned	 to	 2-FAM-IP5,	 but	
did	 suggest	 perturbations	 in	 the	 structure	 of	 N-lobe	 of	 AtIPK1,	 as	 seen	 upon	




BiPh1 101.5 19.31 29.69
BiPh2 66.09 65.53 38.72
BiPh3 76.81 18.43 30.48















phosphatases	 including	SHIP1.	The	compound	 increased	the	phosphorylation	of	Akt	 in	








Like	 the	 former	 study,	 the	 polarisation	 assay	 confirms	 the	 specificity	 of	 SHIP2cd	 over	
SHIP1cd.	The	IC50	value	of	0.99±1.1	μM,	though	remarkably	similar	to	that	of	Suwa	et	
al.	 (2009),	 cannot	 be	 meaningfully	 compared	 with	 results	 of	 assays	 performed	
differently	 in	 other	 studies	 as	 IC50	 does	 not	 account	 for	 differences	 in	 protein	 and	




Figure	 4.14	 –	 Displacement	 of	 2-FAM-IP5	 by	 AS	 1949490,	 a	 SHIP2	 inhibitor	 with	 a	 reported	 30-fold	 decreased	
affinity	for	SHIP1.	(A)	SHIP1cd.	(B)	SHIP2cd.	



































by	progressive	displacement	of	probe	 from	SHIP2,	providing	 indirect	evidence,	 that	2-
FAM-IP5	binds	in	the	active	site	of	5-phosphatases,	or	at	least	in	the	active	site	of	SHIP2.	
	
3-α-aminocholestane	 (3AC)	 was	 identified	 by	 high	 throughput	 screening	 to	 be	 a	
selective	inhibitor	of	SHIP1	(Brooks	et	al.,	2010).	The	assay	used	was	a	commercial	assay	
from	Echelon	Biosciences,	Utah,	USA.	While	the	mechanism	of	action	is	undefined	the	
similarity	of	 structure	with	pelorol,	 an	 allosteric	 activator	of	 SHIP1	 (Yang	et	 al.,	 2005)	















Irrespective	 of	 whether	 3AC	 can	 be	 considered	 an	 analog	 of	 pelorol	 or	 its	 synthetic	
derivatives,	these	remarkable	results	strongly	indicate	that	3AC	is	an	allosteric	regulator	
of	 SHIP1	 that	 acts	 on	 the	 catalytic	 domain	of	 the	protein.	While	 these	 results	 do	not	
directly	call	 into	question	the	reported	mode	of	action	of	pelorol	derivatives	that	have	
entered	Phase	2	clinical	trials	for	inflammatory	disorders	(Blunt	and	Ward,	2012),	they	






standard	error	but	 includes	3AC	concentrations	below	1	μM.	Concentrations	 are	plotted	on	 a	 log10	 scale	 rather	 than	requiring	
concentrations	 to	be	input	and	plotted	 in	log10	 (resulting	in	some	negative	x-coordinates).	Therefore,	in	this	instance	it	offers	a	
more	complete	and	accurate	binding	curve	and	EC50.	




















The	 UV	 absorption	 and	 novel	 fluorescence	 properties	 of	 the	 benzene	 and	 biphenyl	
phosphates	have	been	unearthed	and	characterised.	Work	is	currently	continuing	with	
collaborators	as	to	what	attributes	give	these	compounds	fluorescent	properties	via	use	





The	 biphenyl	 phosphates	 have	 been	 shown	 to	 be	 substrates	 of	 SHIP1	 and	 SHIP2	 as	
opposed	to	inhibitors,	and	have	provided	a	useful	tool	for	the	studying	the	enzymology	
of	 these	 5-phosphatases	 via	 their	 fluorescent	 properties.	 An	 ion	 exchange	
chromatography	method	provides	a	sensitive	means	of	detecting	the	metabolism	of	the	
biphenyl	 phosphates	 and	 in	 future	 can	 be	 extended	 and	 refined	 to	 extract	 kinetic	
parameters	 for	 SHIP1	 and	 SHIP2	with	 the	 fluorescent	 substrate	mimics.	 This	 has	 also	
revealed	 differing	 substrate	 specificities	 between	 SHIP1	 and	 SHIP2	 for	 the	 biphenyl	













A	 robust	 high	 through	 put	 fluorescence	 polarisation	method	 has	 also	 been	 described	
which	 allowed	 the	 construction	 of	 dose-response	 curves	 giving	 descriptions	 of	 the	
binding	 of	 fluorescently	 tagged	 inositol	 phosphate	 analogs	 to	 AtIPK1,	 SHIP1cd,	 and	
SHIP2cd.As	mentioned	 earlier,	 attempts	 to	 obtain	 crystal	 structures	 of	 these	 proteins	
with	 2-FAM-IP5	 are	 on-going.	 It	 is	 reasonable	 to	 assume	 that	 these	 fluorescent	





phosphate-binding	 proteins	 for	 potential	 ligands	 or	 inhibitors	 via	 displacement	 of	 2-















process	 of	 target	 identification	 and	 validation;	 a	 multifaceted	 process	 that	 can	 take	
many	years	to	settle	on	selecting	a	target	for	costly	drug	discovery	(Hughes	et	al.,	2011).	






inhibitor	 (IC50	 =	 0.62	 µM)	 which	 increased	 Akt	 phosphorylation	 and	 reduced	 blood	
glucose	levels	in	mice	(Suwa	et	al.,	2009).	The	identification	of	the	SHIP1	inhibitor	3-α-
aminocholoestane	(3AC)	was	also	identified	via	a	high	throughput	screen	(Brooks	et	al.,	
2010).	 The	 screen	 used	 was	 the	 original	 version	 of	 the	 National	 Cancer	 Institute’s	
diversity	 set	 (see	 section	 5.3)	which	 is	 freely	 available,	 and	 a	 subsequent	 version	 has	
been	used	in	this	work.	3AC	was	identified	as	a	hit	by	use	of	a	fluorescence	polarisation	
method	 that	 detects	 the	 5-phosphatase	 activity	 of	 SHIP1,	 developed	 from	 an	 assay	
available	 from	 Echelon	 Biosciences	 (Drees	 et	 al.,	 2003).	 More	 recently,	 a	 study	 has	
developed	 an	 assay	 and	 screening	 strategy	 that	 is	 applicable	 to	 5-phosphatase	 and	
phosphoinositide-metabolising	enzymes,	and	from	this	a	specific	OCRL/INPP5B	inhibitor	











and	 validation	 of	 high	 throughput	 screening	 assays,	 that	 ultimately	 can	 be	 used	 to	






three	 standard	 deviations	 above	 the	 mean	 of	 the	 negative	 control.	 This	 creates	 a	
separation	band	which	is	defined	by	these	two	thresholds.	The	difference	between	the	
two	mean	values	is	called	the	dynamic	range,	and	dividing	the	separation	band	by	this	




Lipinski's	 rule	 of	 five	 (or	 Pfizer's	 rule	 of	 five)	 is	 a	 simple	 rule	 of	 thumb	 which	 is	
commonly	 cited	 as	 a	 means	 by	 which	 to	 compare	 the	 similarity	 of	 compounds	 with	




impact	 of	 a	 potential	 drug’s	 physicochemical	 properties	 on	 absorption,	 partition	 (or	



















polarisation	 method	 has	 been	 developed	 for	 probing	 the	 active	 sites	 of	 inositol	
phosphate-binding	 proteins,	 the	 proteins	 in	 this	 study	 were	 subjected	 to	 two	 high	
throughput	 screens.	 Any	 inhibitor	 hits	 were	 followed	 up	 with	 binding	 curves	 to	
eliminate	false	positives	and	then	for	AtIPK1,	 taken	forward	for	binding	and	 inhibition	









For	 high	 throughput	 screening	 of	 drug	 discovery	 screens,	 assay	 conditions	 were	 as	






Changes	 in	 protein	 folding	 consequent	 on	 ligand	 binding	 or	 other	 treatments	 were	
reported	by	 the	 intrinsic	 fluorescence	of	2	µM	AtIPK1	protein	as	described	previously	
(Banos-Sanz	 et	 al.,	 2012).	 Additions	 were	 made	 of	 inositol	 substrate	 or	 inhibitor	










at	 25	 °C	 along	 with	 either	 a	 no	 enzyme	 or	 no	 substrate	 control.	 Each	 experiment	
consisted	 of	 3	 replicates	 of	 each	 condition.	 Initial	 linear	 rates	 were	 calculated	 using	











As	 introduced	 in	 section	 5.1.1	 large	 compound	 libraries	 are	 frequently	 used	 in	 the	
search	 for	 lead	 compounds	 for	 subsequent	 optimisation	 in	 inhibitor	 design	 and	
discovery	of	drugs	targeted	towards	proteins	whose	functions	are	implicated	in	human	
disease.	 Phosphoinositides	 and	 their	 soluble	 inositide	 counterparts,	 as	 discussed	
through-out	 this	 text,	 have	 been	 reported	 in	 multiple	 fundamental	 pathways	 of	 cell	




using	 the	 fluorescence	 polarisation	 method	 developed	 in	 chapter	 4.	 The	 work	
demonstrates	the	versatility	of	this	type	of	assay	and	the	fluorescent	probes	at	its	core.	
	
Libraries	 were	 obtained	 from	 the	 National	 Cancer	 Institute	 (NCI)	 through	 the	 Drug	
Synthesis	 and	 Chemistry	 Branch	 (DSCB)	 of	 the	 Developmental	 Therapeutics	 Program	
(Maryland,	 USA),	 where	 they	 are	 freely	 available	 upon	 request.	 Two	 libraries	 were	
subsequently	 screened	 with	 both	 AtIPK1	 and	 SHIP2cd;	 Diversity	 set	 II	 (DivII)	 and	





increasing	 increments	 of	 screen	 compound/potential	 inhibitor	 to	 fixed	 protein	 and	
probe	concentrations,	a	single	concentration	of	compound	was	used	(12.5	μM)	to	allow	











below	 3	 standard	 deviations	 from	 the	 mean	 of	 the	 negative	 control	 is	 a	 “hit”	 and	
therefore	a	potential	 ligand/inhibitor	(see	section	5.1.2).	Due	to	the	robustness	of	the	
method	developed	in	this	study,	and	the	small	errors	generated	by	the	plate	reader,	a	
small	 standard	 deviation	 was	 achieved	 and	 thus	 resulted	 in	 an	 elevated	 number	 of	
potential	 hits.	 Upon	 closer	 inspection,	 many	 compounds	 were	 discounted	 due	 to	







Eventually,	 potential	 hits	 were	 chosen	 rather	 more	 empirically	 by	 assessing	 which	
compounds	gave	a	larger	and	more	considerable	decrease	in	polarisation;	more	akin	to	
approximately	 12	 standard	 deviations	 from	 the	 mean	 of	 the	 negative	 control	 rather	
than	3.	The	Diversity	Set	II	screen	contained	1872	compounds	and	this	scrutiny	helped	
simplify	 the	 process	 of	 finding	 compounds	 to	 follow	 up	 and	 take	 forward	 for	 further	
investigation.	Unfortunately,	this	means	that	true	hits	may	have	been	by-passed.	
	





observed	 decrease	 in	 polarisation	 of	 227.43	mP	 from	 the	mean	 negative	 control	 for	
AtIPK1.	
	 	
Figure	 5.1	 –	 Results	 of	 the	 Diversity	 Set	 II	 screen	 for	 AtIPK1,	 polarisation	 results	 for	 each	 compound	 are	
randomised	 for	 visual	 purposes	 and	 raw	 polarisation	 values	 plotted	 against	 the	 y-axis.	 Points	 shown	 in	 red	






















Set	 II	 since	 discovering	 that	 some	 compounds/inhibitors	 caused	 an	 increase	 in	
polarisation	 of	 the	 probe	 (chapter	 4).	 The	 lower	 value	 of	 polarisation	 of	 maximally	
bound	 probe	 was	 achieved	 with	 a	 lower	 concentration	 of	 protein.	 Increases	 in	
polarisation	 imply	 an	 increased	 affinity	 between	 the	 protein	 and	 probe	 (2-FAM-IP5),	
while	 decreases	 imply	 displacement	 of	 2-FAM-IP5.The	 arrow	 in	 figure	 5.2	 indicates	 a	
compound	 that	 appeared	 to	 displace	 the	 probe	 from	 all	 three	 proteins	 tested.	






As	 demonstrated	 in	 chapter	 4,	 a	 reported	 SHIP1cd	 inhibitor	 (3-α-amino-cholestane,	
3AC)	 increased	 affinity	 of	 SHIP1cd	 for	 2-FAM-IP5.	 The	mechanism	 of	 action	 of	 3AC	 is	
unknown,	 but	 is	 intriguing,	 particularly	 when	 considering	 that	 the	 binding	 partner	
studied	 here	 is	 the	 catalytic	 domain	 not	 the	 full-length	 protein.	 Consideration	 of	
potential	mechanisms	 prompted	 re-inspection	 of	 the	 screen	 shown	 in	 Fig.	 5.2.	 Some	
hits	 that	produced	 increases	 in	polarisation	with	 SHIP1cd	were	 subsequently	 selected	
for	further	scrutiny	(Figure	5.2	-	C).	Overall,	screening	against	SHIP1cd	gave	6	additional	










Figure	 5.2	 –	 Results	 of	 the	 Approved	Oncology	 Drugs	 Set	 V	 screen	 for	 (A)	 AtIPK1,	 (B)	 SHIP2cd	 &	 (C)	 SHIP1cd.	
Polarisation	results	 for	each	 compound	are	randomised	for	visual	purposes	 and	raw	polarisation	values	plotted	














































As	 stated	 previously	 in	 chapter	 4,	 it	 is	 inherent	 in	 the	 interpretation	 of	 experiments	
performed	in	this	chapter	that	2-FAM-IP5	is	an	active	site	ligand	of	the	proteins	tested.	
For	 AtIPK1,	 chapter	 3	 provides	 categorical	 structural	 data	 showing	 the	 biphenyl	
phosphates	 ligands	 co-ordinate	 inositol	 phosphate-coordinating	 residues	 in	 the	 active	
site	of	AtIPK1.	The	displacement	data	presented	in	chapter	4	also	provides	compelling	
evidence	 that	 benzene	 and	 biphenyl	 phosphates	 are	 active	 site	 ligands	 of	 SHIP2	 and	
SHIP1,	 which	 was	 first	 described	 when	 biphenyl	 2,3’,4,5’,6	 -	 pentakisphosphate	 was	
resolved	 in	 the	 structure	 of	 SHIP2	 (Mills	 et	 al.,	 2012)	 That	 benzene	 phosphates	 and	
biphenyl	phosphates	displace	2-FAM-IP5	from	AtIPK1,	SHIP2cd	and	SHIP1cd	is	therefore	
itself	convincing	enough	evidence	that	2-FAM-IP5	is	an	active	site	probe	of	both	classes	
of	protein.	Additionally,	bona	 fide	 substrates	were	able	 to	displace	2-FAM-IP5	 (Figure	


















probe	for	 identifying	potential	 therapeutic	agents	targeting	 inositol	phosphate	kinases	
and	inositol	polyphosphate	5-phosphatases.	
	
All	 compounds	 identified	 as	 ‘hits’	 and	 taken	 further	 for	 determination	 of	 dose-
responses	were	 re-inspected	 for	 optical	 properties,	 UV	 absorbance	 and	 fluorescence,	
that	might	give	rise	to	their	false	identification	as	‘hits’.	UV	spectra	were	run	in	a	96-well	
quartz	 glass	 plate	 on	 a	 Hidex	 Sense	 plate	 reader	 at	 100	 μM	 concentration,	 while	
fluorescence	 emission	 spectra	were	 run	 in	 384-well	 plates	 on	 a	 BMG	ClarioStar	 plate	
reader	with	excitation	band	width	16nm	centered	on	485nm	and	emission	centered	on	





For	 determination	 of	 dose-responses,	 probe	 (2-FAM-IP5)	 at	 2	 nM	 concentration	 was	
incubated	 with	 protein	 at	 200	 nM	 and	 ‘hit’	 compounds	 were	 titrated,	 according	 to	
compound,	 up	 to	 concentrations	 generating	 a	 4-parameter	 fit	 sigmoidal	 curve	









titrating	 ligand	 at	which	 the	 raw	 vertical	 and	 horizontal	 polarised	 emissions	 of	 probe	
were	 not	 ‘greatly’	 altered	 by	 ligand.	 Some	 of	 the	 curves	 do	 not	 therefore	 reach	 a	
minimum	asymptote.	
	
Where	 the	 data	 allowed,	 IC50	 values	 were	 determined.	 IC50s	 obtained	 from	 such	
experiments	 are	 not	 intrinsic	 inhibition	 constants;	 that	 is	 they	 reflect	 the	 local	
conditions	of	the	experiment	and	depend	on	the	concentration	of	displaced	probe	and	
concentration	 of	 protein.	 Nevertheless,	 in	 experiments	 in	 which	 different	 displacing	
ligands	are	 titrated	against	 a	 common	probe	and	common	protein	 concentration,	 the	
IC50	 values	 obtained	 do	 reflect	 in	 a	 meaningful	 way	 the	 affinities	 of	 the	 different	
titrated	 ligands	 for	 target	 protein.	 Such	 IC50	 experiments,	 polarisation-based	 or	
otherwise,	are	the	basis	of	many	pharmaceutical	screens	commonly	performed	at	 the	
initial	 stage	 of	 screening	 programs	 at	 a	 single	 concentration	 of	 ligand	 against	 fixed	
probe	and	protein	concentration	with	millions	of	 individual	compounds	from	chemical	








Figure	 5.3	 compares	 the	 displacement	 of	 2-FAM-IP5	 from	 AtIPK1	 and	 SHIP2cd	 by	
purpurogallin,	an	aglycone	of	various	glycosides	obtained	from	oak	bark	which	has	been	
affiliated	 with	 antioxidant	 properties	 in	 cardiocytes	 (Wu	 et	 al,	 1996).	 Its	 structure	 is	
related	to	catechol,	1,2-dihydroxybenzene,	and	it	has	been	shown	to	inhibit	chatechol-
O-methyltransferase	 (Lambert	 et	 al.,	 2005)	 as	 well	 as	 innate	 immunity	 pathways	
consequent	 on	 activation	 of	 the	 Toll-like	 receptor	 2,	 in	 which	 downstream	 signaling	
from	TNF-α	and	IL-1β	is	repressed	(Cheng	et	al.,	2012).	
	
Titration	 of	 purpurogallin	 against	 IPK1	 and	 SHIP2cd	 revealed	 IC50s	 respectively	 of	
5.5±1.1	and	1.6±1.2	μM,	with	a	smaller	Hill	Slope	for	SHIP2cd	(Figure	5.3).	The	range	of	
the	assay	was	300	mP	and	250	mP	respectively,	the	difference	in	these	upper	plateaus	is	
likely	 determined	 by	 the	 differing	 proteins	 and	 their	 relative	 starting	 affinities	 for	 2-
FAM-IP5.	 They	 both	 reach	 the	 pre-determined,	 ‘target	 gain’	 set	 at	 35	 mP,	 a	 value	
representing	the	intrinsic	polarisation	of	un-bound,	free,	2-FAM-InsP5	probe	in	solution.	
 
Interestingly,	 purpurogallin	 has	 been	 identified	 as	 a	 ligand	 occupying	 the	 nucleotide	
binding	 site	 of	 cyclin-dependent	 kinase	 2	 (cdk2)	 by	 a	 screening	 assay,	 backed-up	 by	
structural	 data	 (Martin	 et	 al.,	 2012).	 CDK’s	 are	 serine/threonine	 kinases	 and	 their	
deregulation	 has	 been	 implicated	 in	 a	 range	 of	 diseases	 including;	 cancer,	
neurodegenerative	and	inflammatory	diseases	(Zhang	et	al.,	2009,	Bain	et	al.,	2007).	A	
second	structure	is	also	available	in	complex	with	human	thymidylate	synthase	(Lesa	et	
al.,	 2012	 –	 to	 be	 published).	 As	 IPK1	 is	 a	 reversible	 nucleotide	 to	 inositol	 phosphate	
phosphotransferase	 (Phillippy	et	al.,	 1994,	González	et	al.,	 2010),	 the	 identification	of	
purpurogallin	 as	 a	 ligand	 is	 perhaps	 explained	 by	 the	 dual	 substrate	 nature	 of	 this	













































Figure	 5.4	 compares	 the	 displacement	 of	 2-FAM-IP5	 from	 AtIPK1	 and	 SHIP2cd	 by	
5,6,7,8,4’-pentahydroxyflavone,	also	known	as	nortangeretin.	The	same	compound	was	





assay	 was	 approximately	 300	 mP	 and	 250	 mP	 respectively,	 and	 both	 dose-response	
curves	reach	the	pre-determined	lower	limit	of	35	mP	which	represents	polarisation	of	
the	free	probe	in	solution.	








































Figure	 5.5	 compares	 the	 displacement	 of	 2-FAM-IP5	 from	 AtIPK1	 and	 SHIP2cd	 by	
Galloflavin,	which	is	commercially	sold	as	a	lactate	dehydrogenase	(LDH)	inhibitor	that	
can	 uniquely	 exert	 its	 effect	 on	 both	 isoforms	 of	 the	 enzyme	 (Manerba	 et	 al.,	 2012).	
Galloflavin	 has	 recently	 been	 shown	 to	 reduce	 lactate	 levels	 in	 adenocarcinoma	 cells	
which	 subsequently	decreases	 their	migration	ability.	 This	was	 the	 result	of	 inhibiting	




1.6±1.2	 μM.	 Like	 the	 previous	 dose-response	 curves,	 the	 range	 of	 the	 assay	 was	
approximately	 300	mP	 and	 250	mP	 respectively,	 and	 both	 curves	 approach	 the	 pre-

















































for	 discriminating	 between	 small	 structural	 changes	 in	 the	 displacing	 ligand.	 Such	
chemical	 modifications	 are	 commonly	 explored	 when	 ‘hits’	 are	 subjected	 to	 lead	
optimisation	 and	 subsequent	 selection	 of	 a	 candidate	 molecules	 for	 clinical	
development	(Hughes	et	al.,	2011).		
	
Even	 without	 detailed	 modeling	 of	 the	 interaction	 of	 these	 ‘hits’	 with	 the	 protein	
subjects,	it	is	clear	that	there	are	striking	similarities	in	the	structure	of	the	compounds	




hydroxyl	 groups	 on	 a	 single	 benzene	 ring,	 and	 exhibit	 a	 carbonyl	 group	 on	 a	 second	
distinct	 ring.	 Without	 structures	 of	 AtIPK1	 or	 SHIP2cd	 in	 complex	 with	 these	
compounds,	 it	 is	 difficult	 to	 reason	 exactly	 how	 purpurogallin,	 5,6,7,8,4’-
pentahydroxyflavone,	 or	 galloflavin	 would	 coordinate	 within	 the	 active	 site	 of	 these	
proteins,	 other	 than,	 as	mentioned	 above,	 it	 has	 been	 shown	 that	 purpurogallin	 is	 a	
nucleotide-binding	site	ligand	of	cdk2	(Martin	et	al.,	2012).		
	
As	 introduced	 previously,	 SHIP2cd	 has	 several	 commercially	 available	 inhibitors	
including	AS1938909	and	AS1949490	(Suwa	et	al.,	2009,	Suwa	et	al.,	2010).	Though	in	
themselves	 similar,	 there	 are	 no	 immediately	 apparent	 similarities	 between	 these	
inhibitors	and	the	compounds	tested	here,	nor	is	there	currently	any	mechanistic	insight	
in	 to	 how	 they	 exert	 their	 inhibitory	 action	 on	 SHIP2,	 therefore	 at	 this	 point	 no	
meaningful	 comparison	 can	 be	made	 between	 them.	 Nevertheless	 these	 papers	 and	
that	of	 Ichihara	and	coworkers	 (Ichihara	et	al.,	2013)	who	modified	a	4-substituted	2-
pyridin-2-ylamide	 scaffold	 derived	 rationally	 from	 a	 comparison	 of	 the	 structures	 of	
AS1949490	 and	 NGD-61338,	 a	 SHIP2	 inhibitor	 from	 NeoGenesis	 Pharmaceuticals	 Inc	
(Annis	 et	 al.,	 2009)	 indicate	 the	 kind	 of	 medicinal	 chemistry	 approach	 that	 can	 be	




bioavailability	 of	 lead	 compounds.	 In	 the	 case	 of	 Ichihara	 et	 al.	 (2013),	 the	 primary	























of	 contrast,	 the	 inositide	 binding	 site	 is	 not	 located	 between	 two	moveable	 lobes	 in	

















some	 of	 the	 EU	 European	 Medical	 Agency.	 These	 belong	 to	 the	 National	 Cancer	
Institute’s	Approved	Oncology	Drugs	Set	V	(AODV).		
	
As	 for	 the	 DivII	 screen,	 the	 experiments	 described	 below	 are	 an	 extension	 of	 the	
unbiased	 screen	 shown	 above	 (Figure	 5.2).	 They	 were	 designed	 to	 provide	 proof	 of	




dose-responses	 were	 re-inspected	 for	 optical	 properties,	 UV	 absorbance	 and	
fluorescence,	 that	 might	 give	 rise	 to	 their	 false	 identification	 as	 ‘hits’	 (results	 not	
shown).	
	
For	 determination	 of	 dose-responses,	 probe	 (2-FAM-IP5)	 at	 2	 nM	 concentration	 was	
incubated	 with	 protein	 at	 200	 nM	 and	 ‘hit’	 compounds	 were	 titrated,	 according	 to	
compound,	 up	 to	 concentrations	 yielding	 on	 4-parameter	 fitting	 sigmoidal	 curves	









constructed	 for	each	 in	which	 the	decrease	 in	polarsiation	 indicates	 that	2-FAM-IP5	 is	
being	displaced	from	all	three	proteins	(Figure	5.8).	For	all	three	proteins	the	curves	are	
not	complete	and	did	not	reach	the	lower	plateau	for	the	free	un-bound	probe,	and	in	
this	 case	 accurate	 IC50s	 could	 not	 be	 calculated	 by	 the	 graph	 fitting	 software.	
Nevertheless,	 a	 clear	 observation	 can	 still	 be	 made	 and	 the	 polarisation	 unarguably	
decreases.	 The	 range	 of	 the	 assay	 varies	 between	 each	 protein.	 Most	 notably	 for	
SHIP1cd	 (Figure	5.8-	C),	but	 this	 is	 a	 result	of	 the	polarisation	gain	 for	 the	 free	probe	
being	 adjusted	 to	 account	 for	 any	 increases	 in	 polarisation	 as	 observed	 by	 SHIP1cd	
previously	 (Figure	 4.15).	 The	 theoretical	 maximum	 for	 polarisation	 is	 400	 mP	 and	
without	adjustment,	any	increase	in	polarisation	would	likely	go	unresolved.	For	AtIPK1	




All	 compounds	 in	 the	 AODV	 screen	 are	 approved	 as	 oncology	 drugs,	 of	 which	
estramustine	sodium	phosphate	is	a	chemotherapeutic	agent	that	has	been	used	in	the	
































































From	 the	 initial	 screening	 process	 valrubicin	 emerged	 as	 a	 positive	 hit	 for	 all	 three	
proteins	 tested.	 However,	 upon	 titration	 against	 the	 2-FAM-IP5	 bound	 proteins	 no	
decrease	 in	 polarisation	 was	 observed	 for	 SHIP1cd,	 only	 with	 AtIPK1	 and	 SHIP2cd	
(Figure	5.9).	As	with	estramustine	phosphate,	the	curves	are	not	complete	and	did	not	
reach	the	lower	plateau	for	the	free	un-bound	probe,	and	accurate	IC50s	could	not	be	
calculated	by	 the	graph	 fitting	 software.	Nevertheless,	a	 clear	observation	can	still	be	
made	 and	 the	 polarisation	 unarguably	 decreases.	 For	 SHIP2cd,	 the	 polarisation	 has	
decreased	 further	 indicating	 that	 at	 the	 highest	 concentration	 of	 valrubicin	 tested	 2-



















































titration	 of	which	 against	 2-FAM-IP5	 bound	AtIPK1	 can	 be	 seen	 in	 Figure	 5.10.	Unlike	









Again,	 it	 has	 an	 interconnected	 ring	 structure,	 consisting	 of	 a	 benzene	 and	 a	
































inhibitor	 (Vultur	 et	 al.,	 2008)	 that	 has	 found	 use	 in	 treatment	 of	 chronic	 myeloid	





upper	 asymptote,	 that	 is	 10-fold	 higher	 than	 that	 of	 3AC.	 While	 the	 5-phosphatase	
family,	or	certainly	the	catalytic	domain	of	this	family,	 lack	obvious	nucleotide	binding	
















































As	reported	 in	chapter	3,	AtIPK1	undergoes	 large	conformational	changes	upon	 ligand	
binding,	most	notably	in	the	N-lobe	of	the	protein.	The	use	of	the	intrinsic	tryptophan	
fluorescence	of	AtIPK1	to	monitor	protein	folding	consequent	on	ligand	binding	or	other	
treatments	 has	 previously	 been	 reported	 (Banos-Sanz	 et	 al.,	 2012).	 AtIPK1	 has	 four	
tryptophan	residues;	W13,	W69,	W129	and	W381.	As	a	 ligand	binds,	the	environment	
of	the	local	residues	can	change	and	this	in	turn	can	affect	the	fluorescence	properties	
of	 the	 aromatic	 amino	 acids.	 Conformational	 changes	 can	 affect	 these	 residues	
discretely,	or	quenching	of	fluorescence	can	occur	as	an	influence	of	other	residues.	
	
Previous	 to	 this	 study,	 probing	 of	 the	 structure	 of	 AtIPK1	 and	 the	 accessibility	 of	 its	





phosphates	 and	 a	 nucleotide	 substrate	 analogue	 (AMP-PNP)	 to	 assess	 the	 changes	 in	
tryptophan	 fluorescence	 in	 the	binary	and	 ternary	complexes	of	AtIPK1	and	a	W129A	
mutant	 (data	not	 shown).	 Changes	 in	 intrinsic	 fluorescence	upon	 ligand	binding	were	







Figure	 5.12	 demonstrates	 the	 average	 fractional	 loss	 in	 intrinsic	 tryptophan	
fluorescence	 when	 increasing	 concentrations	 of	 IP5	 are	 titrated	 against	 a	 fixed	
concentration	of	AtIPK1.	In	this	instance,	a	one	site-binding	model	was	fitted	to	the	data	
and	 the	 dissociation	 constant	 (Kd)	 calculated	 2.8±0.8	 μM.	 In	 the	 previous	 work	
mentioned	above,	 the	Kd	 for	 IP5	binding	was	 calculated	as	0.35±0.12	μM.	Gosein	and	
Miller	obtained	a	value	for	In(1,3,4,5,6)P5	binding	of	0.6	μM	by	isothermal	calorimetry	
(Gosein	 and	Miller,	 2013).	 Although	 not	 far	 removed	 from	 these	 values,	 the	method	















Kd = 2.75 ± 0.80 µM














one	 site	 binding	model	 curves	 fitted	which	 generated	 dissociation	 constants	 for	 each	
compound.	 Figure	 5.13	 Shows	 the	 resulting	 curves	 and	 Kd	 for	 the	 three	 compounds	








μM	 and	 7.7±1.9	 μM	 respectively.	 At	 the	 highest	 concentration	 of	 compound,	




As	 a	 rule	 of	 thumb,	 various	 authors	 suggest	 limiting	 the	 absorbance	 of	 extrinsic	
fluorophore	probes	to	values	<	0.05	to	minimise	inner	filter	effects,	or	the	use	of	short	
path	 length	 cuvettes	 to	 reduce	 the	 effect.	 Clearly,	 the	 low	 (single	 figure	 μM)	
concentration	of	AtIPK1	protein	 and	 the	 low	extinction	 coefficient	 of	 aromatic	 amino	
acids	 are	 unlikely	 contributors	 to	 inner	 filter	 effects	 in	 these	 experiments,	 but	 the	
extinction	 coefficient	 of	 purpurogallin	 ε420nm	 is	 2640	 M-1.cm-1	 in	 50	 mM	 pH	 7.0	








420	 nm	 makes	 clear	 that	 the	 effects	 of	 these	 compounds	 observed	 in	 2-FAM-InsP5	
polarisation	experiments	are	minimal,	particularly	when	the	extremely	short	pathlength	








Figure	 5.13	 –	 Fractional	 change	 in	 the	 intrinsic	 fluorescence	 intensity	 of	 AtIPK1	 upon	 binding	 compounds	were	







































DivII	 screen	but	only	emerged	as	hits	 for	AtIPK1.	The	 same	 fluorescence	 titration	and	
one	site	binding	model	analysis	was	carried	out	with	these	compounds	(Figure	5.14).		
	
Chaetochromin	 produced	 the	 lowest	 Kd,	 3.8±1.6	 μM,	 and	 therefore	 exhibited	 the	











































to	 ADP	 occurs	 which	 is	 then	 used	 by	 pyruvate	 kinase	 (PK)	 to	 convert	
phosphoenolpyruvate	 (PEP)	 to	pyruvate.	The	pyruvate	 is	 then	converted	 to	 lactate	by	
lactate	 dehydrogenase	 (LDH)	 using	 a	 hydrogen	 atom	 from	 NADH.	 The	 conversion	 of	
NADH	to	NAD+	is	representative	of	the	turnover	rate	of	ATP	to	ADP	by	AtIPK1,	and	the	














Figure	 5.16	 shows	 preliminary	 data	 for	 the	 inhibition	 of	 AtIPK1	 via	 this	 assay	 by	
increasing	 concentrations	 of	 purpurogallin.	 The	 calculated	 reaction	 rates	 were	
normalised	by	subtracting	the	inhibited	rate	from	the	rate	of	the	non-inhibited	reaction	




the	 ‘inhibitor’	 concentration	 is	 constant,	 the	 slopes	 of	 the	 reaction	 curves	 are	





























Figure	 5.16	 –	 Fractional	 change	 in	 velocity	 of	 the	 phosphorylation	 of	 inositol	 1,3,4,5,6	 pentakisphosphate	 by	
AtIPK1	upon	increasing	concentrations	of	purpurogallin.	
	


































FAM-IP5	 as	 an	 active	 site	 ligand	 of	 inositol	 phosphate-converting	 enzymes	 which	 are	
either	 inositol	 phosphate	 –	 nucleotide	 phosphotransferases	 (AtIPK1)	 or	 inositol	








et	 al.,	 2011).	 Because	 of	 the	 considerable	 therapeutic	 interest	 in	 phosphoinositide	
metabolising	 enzymes,	 there	 remains	 considerable	 interest	 in	 tools	 enabling	







The	efficacy	of	 inhibition	or	activation	of	 these	enzymes	 is	commonly	tested	 in	assays	
which	measure	the	ability	of	compounds	to	inhibit	or	activate	the	release	of	phosphate	
from	 a	 substrate	 in	 vitro.	 Phosphate	 is	 itself	 commonly	 measured	 using	 malachite	
green-	or	molybdate-based	assays	 (Pirruccello	et	al,	2014).	The	same	authors	used	an	
indirect	 polarisation	 based	 assay	 in	 which	 the	 action	 of	 5-phosphatases	 on	
PtdIns(3,4,5)P3	 yield	 a	 PtIns(3,4)P2	 product	 which	 competes	 with	 a	 fluorescent	
PtdIns(3,4)P2	for	a	post	–reaction	added	binding	protein.	While	such	assays	are	readily	







inhibition	 or	 activation	 of	 inositide-	 or	 phosphoinositide-metabolising	 enzymes,	 the	
efficacy	 of	 inhibitors	 or	 activators	 reflects	 binding	 and	 subsequent	 effect	 on	 the	
catalytic	 processing	 of	 bound	 inositide/phosphoinositide	 substrate.	 There	 remains	
opportunity	and	need	for	the	development	of	assays	which	 interrogate	the	binding	of	





and	 phosphoinositide-binding	 enzymes.	 More	 generally,	 these	 enzymes	 include	
inositide-kinases,	 inositide	 phosphotransferases,	 inositide	 phosphatases,	
phosphoinositide	kinases	and	phosphoinositide	phosphatases.	The	strategy	revealed	is	
likely	 applicable	 to	 enzymes	which	 phosphorylate	 inositides	 and	 phosphoinositides	 at	




Crozotinib,	 as	 ligands	 of	 SHIP1cd	 is	 intriguing.	What	 is	more	 remarkable	 is	 that	 both	
these	 compounds	 share	 with	 3-α-aminocholestane	 (chapter	 4),	 a	 known	 specific	
inhibitor	of	SHIP1cd,	but	not	active	on	SHIP2.	That	all	three	ligands	increase	the	affinity	
of	 SHIP1cd	 for	 2-FAM-InsP5,	 but	 not	 SHIP2	 or	 AtIPK1,	 implies	 a	 potential	 common	
mechanism	of	modulation	of	SHIP1.	That	they	increase	the	affinity	for	the	polarisation	
probe	 suggests	 that	 they	 are	 not	 active	 site	 competitors,	 rather	 that	 they	 have	 an	
allosteric	 role.	This	observation	 is	 remarkable,	particularly	 in	 light	of	 the	 identification	
for	 pelorol	 (a	 natural	 compound	 isolated	 from	 the	 marine	 sponge	 Dactylospongia	
elegans)	which	exerts	an	allosteric	 role	as	an	activator	of	SHIP1	catalytic	activity.	This	
allostery	 has	 been	 attributed	 to	 interaction	 with	 the	 C2	 domain,	 not	 the	 catalytic	
domain	(Yang	et	al.,	2005),	SHIP2	possesses	a	C2-domain	but	is	not	sensitive	(Blunt	and	
Ward,	 2012).	 Derivatives	 of	 pelorol,	 include	 AQX-016A,	 AQX-MN100	 and	 AQX-1125,	

















of	 signalling	 from	activated	Akt	 (PKB),	 and	 therefore	 they	 are	 implicated	 in	many	 cell	










Although,	 a	 successful	 ligation	 independent	 cloning	method	 has	 been	 used	 to	 obtain	
overexpression	of	soluble	recombinant	protein	for	in	vitro	assays.		
An	 apo-structure	 of	 SHIP2cd	was	 obtained	 that	was	 in	 agreement	with	 those	 already	
published	(Mills	et	al.,	2012,	Trésaugues	et	al.,	2014).	The	P4IM-containing	loop	that	has	

























of	 SHIP2cd	 to	 further	 crystallisation	 trails	 to	 explore	 conditions	 in	which	 crystals	with	
complexed	protein	can	be	obtained.	Future	efforts	will	be	focused	on	the	elucidation	of	












complex	 with	 nucleotide	 (ADP/ATP)	 and	 inositol	 polyphosphates	 (IP6/IP5),	 led	 to	 the	
characterisation	 of	 three	 conformational	 states;	 the	 open,	 half-closed	 and	 closed	
conformation,	 respectively	 (Banos-Sanz	 et	 al.,	 2012).	 The	 benzene	 and	 biphenyl	
phosphates	 have	 emerged	 as	 useful	 tools	 in	 both	 determining	 the	 specificity	 of	 an	
enzyme,	 since	 they	can	be	designed	 to	 test	various	phosphate	binding	positions	 in	an	
active	site	pocket,	and	in	prospective	design	of	inhibitors.	This	has	led	to	the	elucidation	
of	 the	 complexes	 with	 the	 biphenyl	 phosphates	 presented	 here.	 Complexes	 with	
BiPh(2,3’,4,5’,6)P5	(BiPh1)	and	BiPh(3,3’,4,4’,5,5’)P6	(BiPh3)	confirmed	the	importance	of	
the	 P6	 binding	 pocket	 that	 anchors	 all	 ligands	 into	 the	 active	 site.	 The	 ubiquitous	
occupation	of	this	pocket	across	all	structures	suggests	it	is	the	primary	determinant	of	
binding	orientation	and	forces	the	orientation	of	the	biphenyl	phosphate	ligands	to	an	
























high	quality	data	 sets	 for	complexes	between	AtIPK1	and	BiPh2	/	BiPh4,	although	 the	
presence	of	compound	in	the	inositide	binding	site	has	been	confirmed	the	structures	are	





As	 discussed,	 the	 benzene	 and	 biphenyl	 phosphates	 have	 been	 utilised	 in	 both	
enzymology	 and	 structural	 studies	 with	 inositol	 phosphate-binding	 enzymes,	 and	 are	
mostly	reported	as	inhibitors	(Mills	et	al.,	2008,	Vandeput	et	al.,	2007,	Mills	et	al.,	2016,	
Swarbrick	 et	 al.,	 2015,	Ward	 et	 al.,	 1995,	Mills	 et	 al.,	 2007,	Mills	 et	 al.,	 2012).	 One,	




phosphatase	 family,	 for	 one	 of	 which	 there	 is	 a	 structure	 in	 complex	 with	 BiPh1,	 as	
discussed	 previously	 (Mills	 et	 al.,	 2012).	 The	 assays	 revealed	 firstly	 that	 biphenyl	
phosphate	 are	 substrates,	 and	 that	 the	 biphenyl	 phosphates	 provide	 a	 very	 sensitive	

















the	 turnover	 of	 these	 compounds	 by	 SHIP1cd	 and	 SHIP2cd,	 and	 subsequently	 data	
describing	the	inhibition	of	their	turnover	either	by	bone	fide	substrates	and	standard	or	









6.4	 A	 robust	 fluorescence	 polarisation	 assay	 to	 explore	 ligand	 binding	 and	 its	
application	in	high	throughput	screening	for	lead	compounds		
Large	compound	 libraries	are	now	available,	often	 free	of	charge,	 to	both	private	and	




but	 many	 consist	 of	 time	 consuming	 end-point	 assays,	 such	 as	 the	 malachite	 green	













high	 throughput	 method	 was	 now	 available	 for	 probing	 the	 active	 sites	 of	 inositol	
phosphate-converting	enzymes,	they	were	subjected	to	two	screens	obtained	from	the	
NCI.	 Hits	 from	 the	 fluorescence	 polarisation	 screens	 that	 appeared	 in	 the	 separation	
band,	 were	 subjected	 to	 further	 investigation	 via	 completion	 of	 full	 dose-response	
inhibition	curves.	
Because	 of	 the	 availability	 of	 assays	 of	 AtIPK1	 function	 developed	 already	 in	 the	









of	 a	 ligand.	 In	 sumary,	 the	 fluorescence	 polarisation	 assay	 has	 produced	 a	 high	
throughput	 robust	method	 for	 the	discovery	of	novel	 inhibitors	of	 inositol	phosphate-












































































































































discovered	 by	 high-throughput	 affinity	 selection-mass	 spectrometry	 screening	 of	
combinatorial	libraries.	Comb	Chem	High	Throughput	Screen,	12,	760-71.	
ASTLE,	M.	V.,	HORAN,	K.	A.,	OOMS,	L.	M.	&	MITCHELL,	C.	A.	2007.	The	inositol	polyphosphate	






ARTHUR,	 J.	 S.,	 ALESSI,	 D.	 R.	 &	 COHEN,	 P.	 2007.	 The	 selectivity	 of	 protein	 kinase	
inhibitors:	a	further	update.	Biochem	J,	408,	297-315.	















activation,	 and	 death	 by	 the	 src	 homology	 2	 domain-containing	 5'	 inositol	
phosphatase	(SHIP).	J	Exp	Med,	191,	1545-54.	



















CHI,	 Y.,	 ZHOU,	 B.,	WANG,	W.	 Q.,	 CHUNG,	 S.	 K.,	 KWON,	 Y.	 U.,	 AHN,	 Y.	 H.,	 CHANG,	 Y.	 T.,	
TSUJISHITA,	 Y.,	 HURLEY,	 J.	 H.	&	 ZHANG,	 Z.	 Y.	 2004.	 Comparative	mechanistic	 and	




WANG,	 J.,	 LEIP,	 E.	 &	 GAMBACORTI-PASSERINI,	 C.	 2011.	 Safety	 and	 efficacy	 of	
bosutinib	 (SKI-606)	 in	 chronic	 phase	 Philadelphia	 chromosome-positive	 chronic	






















G.	 D.	 2003.	 Competitive	 fluorescence	 polarization	 assays	 for	 the	 detection	 of	






































L.	 2004.	 Structure	 of	 a	 Human	 Inositol	 1,4,5-Trisphosphate	 3-Kinase:	 Substrate	
Binding	Reveals	Why	It	Is	Not	a	Phosphoinositide	3-Kinase.	Molecular	Cell,	15,	689-
701.	
GOSEIN,	 V.,	 LEUNG,	 T.	 F.,	 KRAJDEN,	O.	&	MILLER,	G.	 J.	 2012.	 Inositol	 phosphate-induced	
stabilization	of	inositol	1,3,4,5,6-pentakisphosphate	2-kinase	and	its	role	in	substrate	
specificity.	Protein	Sci,	21,	737-42.	
GOSEIN,	 V.	 &	 MILLER,	 G.	 J.	 2013.	 Conformational	 stability	 of	 inositol	 1,3,4,5,6-
pentakisphosphate	2-kinase	(IPK1)	dictates	its	substrate	selectivity.	J	Biol	Chem,	288,	
36788-95.	
GOSEIN,	 V.	 &	 MILLER,	 G.	 J.	 2013.	 Roles	 of	 phosphate	 recognition	 in	 inositol	 1,3,4,5,6-
pentakisphosphate	2-kinase	(IPK1)	substrate	binding	and	activation.	J	Biol	Chem,	288,	
26908-13.	
GRAF,	 E.,	 EMPSON,	K.	 L.	&	 EATON,	 J.	W.	 1987.	 Phytic	 acid.	A	natural	 antioxidant.	 J.	 Biol.	
Chem.,	262,	1164-1150.	
















IVES,	 E.	 B.,	 NICHOLS,	 J.,	 WENTE,	 S.	 R.	 &	 YORK,	 J.	 D.	 2000.	 Biochemical	 and	 Functional	
Characterization	 of	 Inositol	 1,3,4,5,6-Pentakisphosphate	 2-Kinases.	 Journal	 of	
Biological	Chemistry,	275,	36575-36583.	


















LIPINSKI,	 C.	 A.	 2004.	 Lead-	 and	 drug-like	 compounds:	 the	 rule-of-five	 revolution.	 Drug	
Discovery	Today:	Technologies,	1,	337-341.	






LOEWUS,	 M.	 W.,	 LOEWUS,	 F.	 A.,	 BRILLINGER,	 G.	 U.,	 OTSUKA,	 H.	 &	 FLOSS,	 H.	 G.	 1980.	




































B.	 V.	 2007.	 Novel	 inositol	 phospholipid	 headgroup	 surrogate	 crystallized	 in	 the	
pleckstrin	homology	domain	of	protein	kinase	Balpha.	ACS	Chem	Biol,	2,	242-6.	
MILLS,	S.	J.,	PERSSON,	C.,	COZIER,	G.,	THOMAS,	M.	P.,	TRESAUGUES,	L.,	ERNEUX,	C.,	RILEY,	A.	
M.,	 NORDLUND,	 P.	 &	 POTTER,	 B.	 V.	 2012.	 A	 synthetic	 polyphosphoinositide	
headgroup	surrogate	in	complex	with	SHIP2	provides	a	rationale	for	drug	discovery.	
ACS	Chem	Biol,	7,	822-8.	










MONDAL,	 S.,	 SUBRAMANIAN,	 K.	 K.,	 SAKAI,	 J.,	 BAJRAMI,	 B.	 &	 LUO,	 H.	 R.	 2012.	






J.	 K.,	 BREARLEY,	 C.	 &	MARTINOIA,	 E.	 2009.	 The	 Arabidopsis	 ATP-binding	 Cassette	
Protein	AtMRP5/AtABCC5	 Is	 a	High	Affinity	 Inositol	Hexakisphosphate	Transporter	





J.,	DEMIRJIAN,	 L.,	QASIMI,	 P.,	 RUSCHMANN,	 J.,	 CAO,	 L.	 P.,	MA,	 K.,	 CHUNG,	 S.	W.,	
DURONIO,	 V.,	 ANDERSEN,	 R.	 J.,	 KRYSTAL,	 G.	 &	 MUI,	 A.	 L.	 2007.	 Small-molecule	








PERRY,	 C.	 M.	 &	 MCTAVISH,	 D.	 1995.	 Estramustine	 phosphate	 sodium.	 A	 review	 of	 its	






The	 SH2	 domain	 containing	 inositol	 5-phosphatase	 SHIP2	 displays	
phosphatidylinositol	 3,4,5-trisphosphate	 and	 inositol	 1,3,4,5-tetrakisphosphate	 5-
phosphatase	activity.	FEBS	Lett,	437,	301-3.	
PIRRUCCELLO,	M.,	 NANDEZ,	 R.,	 IDEVALL-HAGREN,	 O.,	 ALCAZAR-ROMAN,	 A.,	 ABRIOLA,	 L.,	

























SHERMAN,	W.	 R.,	 STEWART,	M.	 A.	 &	 ZINBO,	M.	 1969.	Mass	 spectrometric	 study	 on	 the	




SLEEMAN,	M.	W.,	WORTLEY,	 K.	 E.,	 LAI,	 K.	M.,	 GOWEN,	 L.	 C.,	 KINTNER,	 J.,	 KLINE,	W.	 O.,	
GARCIA,	K.,	STITT,	T.	N.,	YANCOPOULOS,	G.	D.,	WIEGAND,	S.	J.	&	GLASS,	D.	J.	2005.	
Absence	of	 the	 lipid	phosphatase	SHIP2	 confers	 resistance	 to	dietary	obesity.	Nat	
Med,	11,	199-205.	
STEPHENS,	L.	R.,	HAWKINS,	P.	T.,	STANLEY,	A.	F.,	MOORE,	T.,	POYNER,	D.	R.,	MORRIS,	P.	J.,	
HANLEY,	M.	 R.,	 KAY,	 R.	 R.	&	 IRVINE,	 R.	 F.	 1991.	myo-inositol	 pentakisphosphates.	




STEVENSON-PAULIK,	 J.,	 BASTIDAS,	 R.	 J.,	 CHIOU,	 S.-T.,	 FRYE,	 R.	 A.	 &	 YORK,	 J.	 D.	 2005.	
Generation	 of	 phytate-free	 seeds	 in	 Arabidopsis	 through	 disruption	 of	 inositol	
















SWEETMAN,	 D.,	 JOHNSON,	 S.,	 CADDICK,	 SAMUEL	 E	 K.,	 HANKE,	 DAVID	 E.	 &	 BREARLEY,	




anticholinergic	 properties	 of	 cynarin	purified	 from	 the	 Illyrian	 thistle	 (Onopordum	
illyricum	L.).	J	Enzyme	Inhib	Med	Chem,	31,	266-75.	
TRÉSAUGUES,	 L.,	 SILVANDER,	 C.,	 FLODIN,	 S.,	 WELIN,	 M.,	 NYMAN,	 T.,	 GRÄSLUND,	 S.,	
HAMMARSTRÖM,	M.,	 BERGLUND,	 H.	 &	 NORDLUND,	 P.	 2014.	 Structural	 Basis	 for	
Phosphoinositide	 Substrate	 Recognition,	 Catalysis,	 and	Membrane	 Interactions	 in	
Human	Inositol	Polyphosphate	5-Phosphatases.	Structure,	22,	744-755.	
TSUJISHITA,	 Y.,	 GUO,	 S.,	 STOLZ,	 L.	 E.,	 YORK,	 J.	 D.	 &	 HURLEY,	 J.	 H.	 2001.	 Specificity	
determinants	 in	 phosphoinositide	 dephosphorylation:	 crystal	 structure	 of	 an	
archetypal	inositol	polyphosphate	5-phosphatase.	Cell,	105,	379-89.	














2008.	 SKI-606	 (bosutinib),	 a	 novel	 Src	 kinase	 inhibitor,	 suppresses	 migration	 and	
invasion	of	human	breast	cancer	cells.	Mol	Cancer	Ther,	7,	1185-94.	
WADA,	 T.,	 SASAOKA,	 T.,	 FUNAKI,	 M.,	 HORI,	 H.,	 MURAKAMI,	 S.,	 ISHIKI,	 M.,	 HARUTA,	 T.,	
ASANO,	T.,	OGAWA,	W.,	ISHIHARA,	H.	&	KOBAYASHI,	M.	2001.	Overexpression	of	SH2-




Synthetic	 inositol	 phosphate	 analogs	 reveal	 that	 PPIP5K2	 has	 a	 surface-mounted	
substrate	capture	site	that	is	a	target	for	drug	discovery.	Chem	Biol,	21,	689-99.	
WANG,	Q.,	YANG,	Z.,	ZHANG,	X.,	XIAO,	X.,	CHANG,	C.	K.	&	XU,	B.	2007.	A	supramolecular-
hydrogel-encapsulated	 hemin	 as	 an	 artificial	 enzyme	 to	mimic	 peroxidase.	Angew	
Chem	Int	Ed	Engl,	46,	4285-9.	
WARD,	S.	G.,	MILLS,	S.	J.,	LIU,	C.,	WESTWICK,	J.	&	POTTER,	B.	V.	1995.	D-myo-inositol	1,4,5-
































ZHANG,	 J.,	 YANG,	 P.	 L.	&	GRAY,	N.	 S.	 2009.	 Targeting	 cancer	with	 small	molecule	 kinase	
inhibitors.	Nat	Rev	Cancer,	9,	28-39.	
ZHANG,	J.	H.,	CHUNG,	T.	D.	&	OLDENBURG,	K.	R.	1999.	A	Simple	Statistical	Parameter	for	Use	
in	Evaluation	and	Validation	of	High	Throughput	Screening	Assays.	J	Biomol	Screen,	4,	
67-73.	
	
